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Chronic liver disease is increasing in prevalence worldwide; however, few medical therapies are 
available to treat liver cirrhosis and failure. Hepatic stellate cell (HSC) activation and trans-
differentiation into myofibroblast-like (MFB-like) cells is a key process in liver injury and 
fibrogenesis. Greater understanding of the role of matrix regulating proteases, such as the 
plasminogen activators, in HSC activation could provide new therapeutic targets for treating 
chronic liver disease. Mice lacking plasminogen activators exhibit delay in liver repair; however, 
their exact functions after liver injury remain unclear. Recent studies in kidney demonstrate that 
low density lipoprotein receptor-related protein 1 (LRP1)-dependent signaling by tissue-type 
plasminogen activator (t-PA) is an essential regulator of the myofibroblast phenotype after 
injury. This study investigated the role of t-PA and LRP1 in HSC activation and in vivo liver 
injury. We find that, in contrast to kidney fibroblasts, exogenous t-PA antagonizes activation of 
primary and immortalized HSCs in vitro. Similar to kidney, these effects are independent of the 
proteolytic function of t-PA and require phosphorylation of LRP1. Antagonism of LRP1 or 
PI3K/Akt signaling pathways is able to prevent t-PA-mediated decreases in α-SMA. During 
recovery following acute liver injury, mice lacking t-PA (globally) or LRP1 (conditionally on 
HSCs) retain higher densities of the α-SMA+ MFB-like cell population compared to control 
mice. These differences are seen at time points that correspond to the appearance of co-
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localization between p-LRP1 and α-SMA, as well as t-PA immunolocalization at sites of α-
SMA-positive cells. Additionally, t-PA may regulate macrophage phenotype and drug 
metabolism, as t-PA null mice exhibit increased macrophage accumulation and lack of normal 
compensatory down-regulation of a key metabolic enzyme after acute injury. Finally, more 
collagen I deposition remains in the livers of t-PA null mice up to two weeks after cessation of 
chronic liver injury, suggesting a decreased rate of matrix turnover. These data reveal that t-PA 
has multiple functions in liver repair and is able to affect the phenotype of several cell types, in 
addition to its classical plasminogen activating role. Further preclinical studies are needed to 
evaluate the clinical potential of using t-PA as a treatment for chronic liver injury and fibrosis. 
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PREFACE 
 
Some people go to graduate school because they’re not sure what they want to do in life and 
hope graduate school will give them time and shelter while they decide. To those who have 
already traveled the road, this may be a laughable strategy as the trials and tribulations you 
encounter in graduate school are not for the faint of heart. You encounter the high of highs (I 
have publishable data!), the low of lows (hypothesis proved wrong…again), frustrations (the pre-
conference or pre-committee meeting data jinx), anxieties (constant fear of getting scooped), 
resignations (I won’t be graduating this year…), and exhilaration (grant got funded!!), amongst 
other emotions. It’s enough to make you wonder if you’re emotionally unstable.  
Despite the roller-coaster of emotions, somewhere along the way, I did a lot of “growing 
up.”  Although I am lucky to be able to say that I came to graduate school purposefully, not as a 
backup or last resort or means to an end, I was still not mentally prepared for the maturation 
process that occurs. The process is partly due to the age at which I pursued my graduate studies 
(mid-late 20s), but also partly due to the life events that ran concurrent to and had to be juggled 
with graduate school: getting married, family sickness and crises, adopting pets, overcoming 
personal fears. I ran my first half-marathon in 2011, with an encore in 2012. The challenge of 
tackling and meeting this fitness goal is an achievement I hold dear and, in many ways, I see as a 
parallel to attaining my degree. The training I received in my graduate studies has been a slow 
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but steady escalation of responsibility and competence to ready me for race day: the embarking 
of my career. Although I do not know what the weather conditions will be like during the “race,” 
I am confident that the lessons I learned and the scars I bear will see me through to the end. I will 
know to keep hydrated (i.e. have a balanced life to keep my energy and motivation up), to pace 
myself (i.e. not take on too much too early), to keep looking for the next mile marker (i.e. set 
goals and milestones to work towards), that finding dependable running buddies makes the road 
easier (i.e. collaborate often and with trustworthy people), that having cheerleaders on the 
sideline helps keep spirits up (i.e. keep family and friends and mentors close), and finally, that 
beyond the achievement of finishing the race, I am a better and fitter person for the training that I 
did to reach my goal. 
I have so many people to thank for the growth as a person and as a scientist that this body 
of work represents. First and foremost, I want to thank my thesis advisor, Dr. Wendy Mars. 
Without you, this project would not have been possible in either conception or completion, and I 
could not have asked for a better or more compatible mentor. You and I have weathered many 
problems, joys, crises, and achievements together, and I want to thank you for always holding 
me as an equal, both in expectation and in regard. For the record, I refuse to take responsibility 
for starting your latte addiction (although I concede that I enable its continuation). Second, I 
would like to thank Dr. George Michalopoulos for being an equally important research mentor 
to me over the last several years. I have learned so much by being a member of the greater 
Michalopoulos lab community, as well as from your generous spirit, practicality, and pure 
curiosity of mind. Next, I’d like to thank the rest of my thesis committee members, Drs. 
Charleen Chu, Jim Funderburgh, Donna Stolz, and Youhua Liu. As an entire committee, 
you all challenged me and asked me hard questions when I needed them, were encouraging and 
 xv 
approving when I was ready, and have individually each been a source of great help and 
encouragement. I could not have asked for a better committee. Of course I need to thank my 
trusty and dynamic labmates, past and present: Bill Bowen, Anne Orr, Kelly Koral, Vishakha 
Bhave, Shashi Donthamsetty, Michael Ding, Shirish Paranjpe, John Stoops, Aaron Bell, 
Meagan Haynes, Hena Bukhari, Rachel Stewart, Jennifer Hurd, Callie Norris, Yu Yang, 
Bowen Liu, Chih-Wen Lin, Akhil Venkatesan, Paul Siebert, Josiah Radder, and Diane 
Hsu. Thank you for enduring my sometimes incessant ranting and raving, my obsessive-
compulsive tendency to rearrange things in the lab, and my futile attempts to fatten you up with 
my baking. I would also like to thank my collaborators, Drs. A. Jake Demetris, Kumiko Isse, 
Selen Muratoglu, and Dudley Strickland. You all helped me take my project from just 
interesting to truly publishable. I appreciate so much your generosity of time and resources. Last 
but not least, I want to fully acknowledge my family and close friends. To my husband and my 
much better half, Michael Sung: I want to thank you for your love, support, sacrifices, laughter, 
and hope for the future. I am so lucky to have found someone awesome to share every step of the 
road ahead. To my parents: thank you for your sacrifices and care throughout my life, for your 
high expectations, and your continual encouragement and support. I love you both and hope to 
keep making you proud. To my little sister, Lena: despite our inherent differences, I hope we can 
continue to foster a close and supportive relationship. My goal has always been and will continue 
to be to encourage you to achieve your potential. You have so much talent and energy! To my 
college roommate and good friend Jessica Keister: we have traveled and eaten the world 
together! I am glad that time and distance has not lessened our friendship in the least, and I look 
forward to a lifetime shared over cats and pastries and bibimbap. To my good friend and running 
buddy, Shannon Svilar: I am so glad to have found you as a friend at this time period in my life. 
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I know we’ll be friends for life, no matter what the distance between us. And finally, to my 
MSTP brothers-in-arms, Vineet Agrawal, David Svilar, Samuel Shin, Pavle Milutinovic, Ben 
Mantell, Amin Afrazi, Vivek Patel, Mark Doyal, Jeff Koenitzer, and David Wheeler: I may 
have been the only female in our class but you always made me feel like “one of the guys” and 
included me as an equal in every way. I am so proud of all of you and to be amongst you, and I 
hope we’ll always keep in touch and collaborate. 
There are so many more people to thank and acknowledge, but for brevity, they are listed 
below: 
 My grandparents, aunts, uncles, and family in Taiwan 
 My parents-in-law, Peter and Leah Sung, and brother-in-law, Paul Sung 
 My Uncle Yangming and Aunt Tracy Chen 
 The Lin family 
 My friend and college roommate, Dara Missan 
 Tim and Kathy Keister 
 My friend, Susan Specht 
 Floormates: the Monga lab, the Strom lab, the Liu lab, and the Zarnegar lab, most 
especially Dr. Emily Wickline, Dr. Prince Awuah, Evan Delgado, Dr. Kari Nejak-Bowen, 
Dee Seneviratne, Dr. Yingjian Li, Lin Lin, and Dr. Marc Hansel 
 Collaborators Dr. Gina Coudriet and Dr. Jon Piganelli 
 My MSTP Career Advisor, Dr. Bruce Pitt 
 MSTP Director Emeritus Dr. Clayton Wiley, current MSTP Director Dr. Richard 
Steinman, Co-director Dr. Nathan Urban, Dr. Manjit Singh, and Justin Markuss 
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 Pathology Medical Student Interest Group faculty advisors, past and present, Drs. Trevor 
Macpherson, Larry Nichols, and Marie DeFrances 
 My endocrinology LCC preceptor, Dr. Maja Stefanovic-Racic 
 My research administration mentor, Dr. Jennifer Woodward 
 My undergraduate research advisor, Dr. Melinda Duncan 
 The SOM Office of Graduate Studies, especially Carol Williams, Clare Gauss, and 
Jennifer Walker 
 CMP Administrative Coordinator Shari Tipton 
 The University of Pittsburgh DLAR and IACUC, especially Nicole Scales, Lindsay 
Bihler, Paula Chalmers, and the staff at the PLUM facility 
 The University of Pittsburgh CTSI Pre-doctoral fellowship program (funding 2009-2011) 
 NIDDK, F30 DK091959 (2011-2014)
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1.0  GENERAL INTRODUCTION 
1.1 THE LIVER AND ITS REGENERATION AFTER INJURY 
Liver is a multi-functional organ that controls key physiological processes. These include 
nutrient processing following intestinal absorption, waste processing and excretion (urea cycle 
and bile synthesis), detoxification of xenobiotics, energy and nutrient storage and regulation, 
production of serum proteins (coagulation factors, oncotic proteins, carrier proteins) and 
hormones (thrombopoietin (1), IGF1), and other functions. 
The ability of the liver to carry out these normal duties is so essential that liver mass is 
maintained within a very narrow range in relation to the overall body mass. If there is loss or 
gain of liver mass, such as through liver injury or pregnancy, respectively, compensatory 
proliferation or apoptosis of cells allows restoration of original liver/body mass ratio once the 
stimulus is removed. The term “hepatostat” has been coined to describe this unique homeostatic 
relationship (2). When the hepatostat is derailed and loss of liver function due to parenchymal 
injury falls below a critical point (build-up of toxic metabolites, inability to maintain glucose 
levels and blood pressure, and coagulopathy), multi-organ failure and death follows. 
The robust programmed proliferative response to loss of parenchymal function is widely 
known as “liver regeneration.” A more accurate description may be “compensatory hyperplasia 
and hypertrophy,” as resection of the liver does not induce spatial replacement of the part of the 
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organ that was lost. Instead, the cells in the remaining portion proliferate and/or increase in size 
to restore the original liver mass (3). Repopulation of the liver can be achieved via one of two 
mechanisms: 1) self-replication of individual cell types, or 2) trans-differentiation from 
facultative stem cells, or liver progenitor cells.  
As management of chronic liver injury and its sequelae are growing health care burdens 
worldwide (4), knowledge of the principles and cellular compartments governing successful 
restoration of liver function after insult is the key to discovering therapeutic strategies applicable 
to human hepatic disease.  
1.1.1 Cell types of the liver 
The main unique cell types of the liver are hepatocytes, cholangiocytes (or biliary epithelial 
cells), Kupffer cells, hepatic stellate cells, and sinusoidal endothelial cells. Hepatocytes are 
organized into cords that line an intricate, specialized capillary bed lined with fenestrated 
endothelial cells (Figure 1A). The vascular network is organized into a system that allows for 
unidirectional flow from branches of the inflow vascular supply, the portal vein and the hepatic 
artery, through the sinusoids to the central veins, which coalesce into the hepatic vein and 
connects to the inferior vena cava. The portal vein and hepatic artery are found in cluster along 
with a collecting bile duct, collectively referred to as the “portal triad,” and spaced out at the 
corners of a roughly hexagonal unit (“the hepatic lobule,” Figure 1B) that is repeated throughout 
the liver tissue. Blood flows away from the portal triads through the sinusoid capillaries, while 
bile flows in the opposite direction through the bile canaliculi, which coalesce into bile ducts 
(shown in Figure 1). In addition, lymphatic vessels are found in portal regions and drain lymph 
that originates from the hepatic sinusoids. As macromolecules pass through the sinusoidal 
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endothelial fenestrae, excess fluid collects in the Space of Disse, the area between the endothelial 
cells and the hepatocytes, and drains towards the portal regions (5). The lobule can be divided 
into three general zones: periportal (zone 1), pericentral (zone 3), and transitional (zone 2). The 
hepatocytes in Zone 1 to Zone 3 are exposed to increasing concentrations of processed 
xenobiotics/toxins and decreasing concentrations of oxygen (Figure 1B). 
The hepatocyte is the parenchymal cell of the liver, performing all the essential functions 
of the organ described in the section above. In addition, the hepatocytes produce bile, secreted 
from the apical membrane into the bile canaliculi that run between hepatocytes and merge to 
form bile ducts, which are lined with cholangiocytes. Cholangiocytes and hepatocytes share a 
common precursor cell, the hepatoblast, in development. This common lineage is attributed 
because of the ability of cholangiocytes and hepatocytes to transdifferentiate in the setting of 
injury where one or the other cannot replicate sufficiently to replace its own cell compartment 
and the other then compensates. The “non-parenchymal cell” population includes sinusoidal 
endothelial cells, Kupffer cells, and hepatic stellate cells. Sinusoidal endothelial cells are 
fenestrated to allow passage of macromolecules and lipoproteins in and out of the hepatocytes. 
Kupffer cells are resident liver macrophages, which along with other liver-associated immune 
cells play important roles in immune tolerance of the liver (6). The hepatic stellate cell is a 
multifunctional cell of mesenchymal origin found to have roles in immune function, vitamin 
storage, matrix turnover, growth factor secretion, vascular tone, and perhaps progenitor cell 
niche. During injury, hepatic stellate cells become “activated” and transform into myofibroblast-
like cells, depositing extracellular matrix and becoming contractile (7).  
During liver regeneration, whether following surgical resection or parenchymal injury 
and loss, all of the cell types of the liver can proliferate to replace their own cell population. 
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When unable to do so, however, there are internal or external (e.g. hematopoietic) sources of 
progenitor cells that are able to differentiate into the various cells of the liver to restore cell 
compartments.  
 
Figure 1. Architecture of the liver. (A) Schematic depicting the architecture and cell type 
composition of the hepatic sinusoid. Blood enters the lobule from branches of the portal vein (PV) and hepatic 
artery (HA) and progresses through the sinusoidal capillaries, collecting at the central veins (CV). Bile flows 
in the opposite direction towards the portal triad and exits through the bile ducts (BD). Hepatocytes are lined 
up along the sinusoids in “plates” 1-2 hepatocytes thick. Hepatic stellate cells reside in between the sinusoidal 
endothelial cells and hepatocytes in the “space of Disse.” (B) Diagram illustrating the organization of the 
hepatic lobule, including vascular structures and relative zonality of the lobule. This unit is repeated 
throughout the liver. Representative plates of hepatocytes are shown for orientation; these rows of 
hepatocytes would fill the entire lobule and be lined with sinusoids. Adapted from (8). 
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1.1.2 Regeneration models 
The two-thirds partial hepatectomy (PHx) model was first described in 1931 (9) and remains one 
of the most widely used models of liver regeneration. The rodent liver is multi-lobular, the two 
largest of which approximates 70% parenchymal mass. When these two lobes are excised via a 
straightforward surgical procedure (10), the cells of the remaining lobes restore liver mass over 
the course of 1-2 weeks. There are two key advantages to this approach: 1) the model is easily 
scalable, allowing investigators to study phenomena associated with minor (~30% PHx) to 
severe (~90% PHx) parenchymal loss simply by removing one less or one more lobe of the liver, 
and 2) because there is no overt injury to the remaining hepatocytes, PHx provides a “clean” 
model in which to study the timing and extent of contribution of different variables, which is less 
optimally studied in injury models using hepatotoxins that are associated with 
necrosis/inflammation. However, the main drawback to this approach is the limited applicability 
of the PHx model for interpreting dynamics of regeneration in human disease, which often 
involves components of hepatocyte death and inflammation. Even in the clinical situations which 
hepatic resection is used, such as for early stage hepatocellular carcinoma or cancer metastases 
from other organs, the process of regeneration may be altered from the ideal due to several 
reasons: 1) prior or concurrent chemotherapeutic treatment, 2) background fibrosis that is 
commonly found with hepatocellular carcinoma, and 3) superimposed ischemia-reperfusion 
injury as a complication of surgery. In addition, PHx alone does not require liver progenitor cells 
for successful regeneration, and thus is not a useful model to study progenitor cell-mediated 
regeneration. 
In comparison, several chemical injury models also exist. These cause hepatocyte injury 
and death, which activates an inflammatory response in addition to a regenerative response. One 
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commonly used class of agents causes hepatocyte injury and death selectively in the pericentral 
zone (Zone 3); these include carbon tetrachloride (11, 12) and acetaminophen (13-15). They 
require metabolic activation by drug-specific cytochrome P450 (CYP) enzymes, a process which 
often generates hepatotoxic free radicals. The CYP-expressing hepatocytes die first, creating a 
centrilobular distribution of injury and death. Allyl alcohol administration has been used to 
induce acute periportal injury (16). There are two main advantages in using a hepatotoxin model 
to study regenerative response after parenchymal injury: 1) it more closely approximates the 
regenerative response that occurs in common human hepatic diseases, including the damage and 
inflammatory infiltrate, and 2) unlike PHx (17), there are few surgical complications with 
repeated administrations, so it is easy to extend the acute injury model to chronic injury and 
cirrhosis. An emerging concept from the hepatic toxicology field is the “progression of injury”: 
primary injured/necrotic hepatocytes release phospholipases (18, 19) and proteases (20) into the 
extracellular space, which then injure neighboring hepatocytes and delay/inhibit their ability to 
undergo normal regeneration. It is likely these processes occur in a variety of acute and chronic 
human liver diseases and intoxications, where there is also in situ hepatocyte injury and death. 
Therefore, despite the relative lack of clarity about cellular origins of signals occurring as a result 
of chemical injury models, the importance of synthesizing our understanding of ideal liver 
regeneration from PHx with data from chemical injury models cannot be understated. It may be 
the key to future understanding of the limitations of current interventions and finding more 
suitable therapeutic targets for human disease and acute intoxication (21, 22).  
A final model of liver growth is augmentative hepatomegaly (also known as “direct 
hyperplasia”), in which liver is stimulated to grow to a supraphysiological mass by growth 
factors, hormones (23-26), or xenobiotics. There are two classes of xenobiotics commonly used 
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in this experimental model: peroxisome proliferator-activated receptor (PPAR) family agonists 
(27) and constitutive androstane receptor (CAR) agonists (28). Continuous administration of 
these chemicals induces liver growth until a new equilibrium is reached, which is different for 
each chemical. Upon removal of the hormone or xenobiotic treatment, however, the liver shrinks 
back to the original mass through hepatocyte apoptosis (29-31). These phenomena suggest that 
the innate hepatostat is disrupted or readjusted in response to these xenobiotics, returning to 
normal when the chemical is removed, although it is not clear which pathways are relevant for 
this purpose. Due to the dependence on specific nuclear receptor pathways, there are some key 
differences between augmentative hepatomegaly and normal liver regeneration (compensatory 
hyperplasia) (32). However, it has been shown that the same genetic alterations that enhance (33) 
or suppress (34) compensatory hyperplasia can also enhance (35, 36) or suppress (37) 
augmentative hepatomegaly, so lessons learned from the augmentative hepatomegaly model may 
bear relevance to enhancing compensatory liver regeneration. There are scenarios where 
augmentative hepatomegaly is clinically relevant: 1) elevated estrogens during pregnancy are 
thought to increase liver weight to meet increased metabolic needs, 2) several prescribed drugs, 
such as phenobarbital (38), phenytoin, and diazepam, can bind to CAR and sensitize the patient 
to acetaminophen toxicity. 
1.1.3 Cellular sources for repopulation in liver regeneration 
1.1.3.1 Resident liver cells 
After PHx, a well-orchestrated set of cell replications occurs amongst the resident cells of the 
liver in order to replace the lost liver mass and function. First and foremost, the hepatocytes 
undergo cell proliferation, with the peak of proliferation being at approximately 24 hours in the 
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rat (39) and approximately 36-42 hours in the mouse (10). Cholangiocytes respond to the same 
mitogenic signals and start proliferating almost as early as hepatocytes, while non-parenchymal 
cells initiate DNA synthesis at a slower pace, with Kupffer cells and stellate cells peaking at 48-
72 hours and sinusoidal endothelial cells at 96 hours (39-41).  
Most hepatocytes participate in cell proliferation during regeneration to restore liver 
mass. In the two-thirds PHx model in younger rats, over 95% of hepatocytes undergo DNA 
synthesis, and this only decreases to about 75%, even in older rats (42-44). Exogenous infusion 
of mitogens can improve the proliferative response in older animals, indicating that age-related 
decreases in hepatocyte proliferation are not due to inherent inability to proliferate (senescence) 
but perhaps changes in the ability to respond to extracellular environment and signals (24, 45). 
The remarkable capacity of hepatocytes to undergo innumerable proliferation cycles is 
demonstrated by successful regeneration after serial PHx (up to 12 documented (46)) and serial 
repopulation of small numbers of isolated hepatocytes into host animal livers with impaired 
native cells (calculated 69 doublings of each cell over six repopulations (47)). Indeed, during 
regeneration hepatocytes express markers of stem cells, or reprogramming factors, such as Oct4, 
Nanog, and KLF4 (48), lending even more credence to their self-renewal capabilities. 
During the regenerative process, hepatocytes can secrete many growth factors to which 
non-parenchymal cells are responsive. These include transforming growth factor-α (TGF-α) (49), 
fibroblast growth factors (FGFs) (50), vascular endothelial growth factor (VEGF) (51), and 
platelet-derived growth factor A (PDGF-A) (52). In turn, the non-parenchymal cells provide 
hepatocytes with many growth factors. New hepatocyte growth factor (HGF) is synthesized by 
stellate cells and endothelial cells (51, 53, 54). Epidermal growth factor (EGF) production 
increases from Brunner’s glands in the duodenum, and heparin-binding epidermal growth factor 
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(HB-EGF) is available from endothelial cells and macrophages (55). Macrophages provide 
interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). The secretion of growth factors by the 
different cell types to regulate hepatocyte proliferation during regeneration is summarized in 
Figure 2A. 
Revascularization of the hepatic plates after proliferation occurs through a signaling 
“conversation” between hepatocytes and endothelial cells. Increases in expression of growth 
factor receptors on endothelial cells during regeneration, such as VEGF receptors Flk-1/KDR 
and Flt-1, allow them to be responsive to hepatocyte-derived VEGF (56). The endothelial cells 
that surround avascular clumps of newly-replicated hepatocytes also selectively express the 
Angiopoietin receptor Tie-1 (56). Activation of these VEGF and Angiopoietin receptors induces 
the endothelial cells to proliferate and invade in between the hepatocytes to form new sinusoids 
(40, 57, 58). 
 
 
Figure 2. Signals and cells contributing to cell repopulation during liver regeneration. (A) Upon loss 
of two-thirds of the liver mass after PHx, molecular signals from several cell types contribute to hepatocyte 
repopulation during regeneration. (B) Both hepatocytes and cholangiocytes undergo self-renewal in normal 
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regeneration; however, trans-differentiation can occur via the relationships indicated. Dotted arrows indicate 
relationships based on newly emerging literature. Adapted from (8). 
 
1.1.3.2 Bone marrow derived cells 
Mobilization of bone marrow has been reported after PHx in rodents (59) and also in humans 
(60). Circulating bone marrow-derived mesenchymal stem cells contribute to new sinusoidal 
endothelial cell repopulation and are a major source of newly synthesized HGF after PHx (61, 
62). It has been a topic of discussion whether circulating bone marrow cells contribute to 
hepatocyte repopulation during regeneration. In experimental models in which hepatocyte 
proliferation was inhibited, hematopoietic lineage cells were able to repopulate a portion of the 
hepatocytes (63, 64). However, more recent studies have suggested that the observations made 
from those experiments were perhaps due to cell fusion events between the bone marrow 
hematopoietic stem cells and hepatocytes (65, 66). 
1.1.3.3 Oval/Progenitor cells and trans-differentiation 
While there is still an ongoing search for conclusive proof of a resident liver stem cell 
population, a variety of studies have established that several liver cell types can act as facultative 
stem cells and trans-differentiate to replace the epithelial cell compartments during regeneration 
(67, 68).  
One of the best-described examples is the emergence of “oval cells” in experimental 
models (e.g. administration of the chemical AAF prior to PHx) and diseases where hepatocytes 
cannot proliferate (69-71). Oval cells are named based on the shape of their nuclei, and they 
express cell markers of both hepatocytes and biliary cells as well as stem cell markers (72); they 
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can be induced to differentiate into either cell type (Figure 2B). They appear in the periportal 
areas, and pulse-chase labeling of these cells with tritiated thymidine in the AAF + PHx model 
indicate that over the course of regeneration, they acquire hepatocyte-associated markers and 
phenotypic characteristics (69). Many of the growth factors discussed earlier in this review have 
been implicated in oval cell differentiation into hepatocytes, such as TGF-α, HGF, transforming 
growth factor-β (TGF-β), and Notch (73-76), although some oval-cell specific signaling 
pathways have been identified (77, 78). Some disagreement exists about the origins of oval cells; 
however, it is likely that they derive from the biliary cell compartment for the following reasons: 
1) most “oval cell markers” are shared markers with biliary cells (cholangiocytes), 2) in 
situations where they appear, such as massive hepatocyte necrosis of the human liver, they 
emanate from and cluster around the portal tract (79), 3) early in oval cell-inducing experimental 
protocols, hepatocyte markers (e.g. hepatocyte nuclear factor 4) appear in the nuclei of biliary 
cells of intact bile ducts prior to the appearance of oval cells, which also express these 
hepatocyte markers (80), and 4) toxin-mediated damage to the bile ducts prior to the AAF + PHx 
protocol can completely prevent the appearance of oval cells (81). As a proliferative biliary 
response, termed “ductular reaction,” is seen in many human liver disease conditions in which 
there is attrition of hepatocytes, it is likely that oval cell-mediated regeneration is relevant to 
human liver regeneration (82). 
Hepatocytes have also been noted to possess trans-differentiation capabilities under 
certain conditions, particularly hepatocytes immediately proximal to the portal tract (67). In 
experiments where hepatocytes positive for the DPPIV marker were injected into DPPIV-
negative rats that had been subjected to PHx and retrorsine intoxication, the regenerated chimeric 
liver possessed no DPPIV-positive bile ducts unless a biliary proliferative stimulus (e.g. bile duct 
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ligation) also accompanied the procedure. In the combined hepatocyte injury and biliary 
proliferation scenario, approximately 1.5% of the bile ducts became DPPIV-positive. If the 
ability of the native cholangiocytes to proliferate was inhibited by the biliary-specific toxin 
methylene dianiline (DAPM), the number of DPPIV-positive bile ducts increased to nearly 50% 
after bile duct ligation + PHx/retrorsine (83), demonstrating the capacity of DPPIV-positive 
hepatocytes to participate in repopulation of the biliary cell compartment. 
Emerging evidence points to a stem cell niche in the hepatic stellate cells of the liver 
(84). One lineage tracing study used GFP to label cells that expressed glial fibrillary acidic 
protein (GFAP), a stellate cell marker, before subjecting mice to a diet-based model of liver 
injury and oval cell activation. After the injury, GFP-positive cells lost stellate cell markers and 
acquired stem/oval cell markers. These transitional cells disappeared as GFP-positive 
hepatocytes emerged (85).  
 
1.2 LIVER INJURY AND FIBROSIS 
1.2.1 Hepatic fibrogenesis 
Hepatic cirrhosis is characterized by extensive scar tissue (fibrosis) that surrounds regenerative 
nodules and initiates extensive vascular changes, altering the liver’s hemodynamic flow. 
Fibrogenesis begins with chronic injury to the liver’s parenchymal cells, the hepatocytes, which 
then recruit an inflammatory milieu that further promotes extracellular matrix remodeling (86).  
Hepatic stellate cells (HSCs) become activated in response to signals such as pro-inflammatory 
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cytokines, growth factors, and reactive oxygen species from both the injured hepatocytes and the 
infiltrating immune cells. Consequently, the HSCs acquire a myofibroblast-like phenotype, 
secreting matrix proteins such as collagen types I and III (87). Other sources of myofibroblasts in 
liver fibrosis may include hepatic portal fibroblasts (88), bone marrow progenitor cells (89), or 
epithelial-to-mesenchymal transition (90, 91). Pro-fibrotic cytokines such as transforming 
growth factor-β1 (TGF-β1) (92) and connective tissue growth factor (CTGF) (93) promote 
sustained synthesis of extracellular matrix components by myofibroblasts.  Paradoxically, HSCs 
are also key regulators of matrix breakdown in the liver, secreting metalloproteinase (MMP)-1, -
2, -3, and -9 and their activators in early liver repair (94, 95). As injury becomes chronic, 
however, they start producing the tissue inhibitors of metalloproteinases (TIMPs), resulting in 
net extracellular matrix accumulation and fibrosis (87, 94), as summarized in Figure 3.  
Occlusion of the extensive liver sinusoidal capillary network within the liver by an 
expanded HSC/myofibroblast population and collagen deposition affects liver hemodynamics by 
increasing intra-sinusoidal resistance. Increased vascular pressures in the liver disallow normal 
processing of dietary nutrients and toxic metabolites, as well as efficient venous blood return to 
the heart from the viscera. In addition, sinusoidal endothelial cells lose their fenestrations during 
liver fibrogenesis (96, 97) and are unable to allow macromolecules to diffuse across the 
endothelium to the hepatocytes (98). In advanced cirrhosis, angiogenesis may also occur in an 
HSC-dependent manner within fibrotic tracts that bridge between larger vessels, shunting blood 
away from sinusoids (99). This alteration in blood flow is detrimental to the hepatocytes, which 
are perfused primarily through the sinusoidal capillaries. As a consequence, derangement in the 
metabolic and synthetic functions of the liver comprises the clinical syndrome of cirrhosis. 
Ultimately, liver cirrhosis can be characterized as a vascular disease process. 
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Figure 3. Progression from liver injury to fibrosis. Hepatic fibrogenesis is a process common to any 
condition that results in chronic inflammation and injury to the hepatocytes (the parenchymal cells of the 
liver). Significant causes include infection, alcoholism, non-alcoholic fatty liver disease (NAFLD), hepatic 
storage diseases, and chemical toxicity (e.g. hepatotoxic medications). Activation of hepatic stellate cells 
(HSCs) is necessary for liver repair after acute injury; however, accumulation of myofibroblasts from chronic 
inflammation and liver injury results in fibrogenesis. It is therefore crucial to remove the underlying 
pathology for resolution of fibrosis to occur. Adapted from (100). 
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1.2.2 Challenges to treating hepatic cirrhosis 
Liver cirrhosis and failure is a leading cause of death in the United States and is the common 
outcome for a variety of chronic liver diseases, including hepatitis B/C, alcoholism, and non-
alcoholic fatty liver disease. Prevalence of liver cirrhosis continues to increase due to the 
Hepatitis C and obesity epidemics worldwide. Currently the only strategy to target liver cirrhosis 
is to treat the underlying liver pathology. Some success has been found with this approach as 
better anti-viral regimens have become standard for hepatitis B and C. However, not all hepatitis 
patients tolerate or respond to therapy, and lifestyle changes associated with alcoholic or fatty 
liver-related cirrhosis are difficult to implement. Therefore, current disease-specific treatments 
are often inadequate or too late to stem the progression to end-stage liver disease, when only 
symptomatic therapy and liver transplant are viable options.   
Only recently have scientists and clinicians realized that regression of established 
cirrhosis may be an achievable goal in patients. In animal models, regression of fibrosis has been 
consistently seen after removal of the chronic hepatic injury and is associated with HSC 
apoptosis and quiescence (101-103). However, in contrast to the relatively quick timeline of 
animal models of fibrosis (weeks), human liver cirrhosis represents up to decades of collagen 
crosslinking and parenchymal remodeling, presenting a more difficult and multi-variable 
challenge for potential anti-fibrotic therapies (104). Therefore, the idea that regression of 
cirrhrosis can also occur in humans has historically been met with some skepticism. Within the 
last decade, however, an increasing number of clinical studies have been published reporting a 
decline in histological fibrosis score with successful therapy for the underlying disease (such as 
hepatitis C) (105). With concurrent greater appreciation of the basic mechanisms of liver 
fibrogenesis, particularly the signaling pathways regulating the deposition of matrix by 
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myofibroblasts and/or survival of these cells, the advent of fibrosis-specific drugs that can be 
adjuvant therapies to disease-specific treatments is on the horizon (106-108).  
1.3 PLASMINOGEN ACTIVATORS 
1.3.1 Structure, function, and clearance of plasminogen activators 
Fibrinolysis is the process by which crosslinked molecules of fibrin are broken down by the 
serine protease plasmin and cleared from a site of injury. As shown in Figure 4, plasmin activity 
is positively regulated by the plasminogen activators and negatively regulated by α2-antiplasmin 
and α2-macroglobulin, collectively referred to as the plasminogen activating system (PAS). 
Tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA) are 
soluble serine proteases present in the serum and various tissues that are known primarily 
because they activate the zymogen plasminogen into its active form, plasmin. Both PAs are 
secreted in a single chain form and can be cleaved into a two-chain form by plasmin and other 
proteases; both single chain and two-chain t-PA can be enzymatically active, while single chain 
u-PA has significantly reduced activity compared to its activated form (109). Both t-PA and u-
PA possess a C-terminal serine protease domain, a zymogen activation site, one (u-PA) or two (t-
PA) kringle domains, and an epidermal growth factor (EGF) domain  (110).  In addition, t-PA 
possesses a fibronectin-type II “finger” domain at its amino-terminal domain (110), as shown in 
Figure 5.   
Regulation of PA function occurs by formation of inhibitory complexes and clearance 
from the extracellular environment.  The PAs have been found to be specifically inhibited by the 
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serpins plasminogen activator inhibitor type-1 and -2 (PAI-1 and PAI-2); however, PAI-1 is 
thought to be the primary physiological inhibitor of the PAs in vivo as most PAI-2 is expressed 
intracellularly (111). The low density lipoprotein-receptor related protein-1 (LRP1; also known 
as the α2-macroglobulin receptor or CD91) and gp330 have been shown to bind and internalize 
u-PA and its complexes (with PAI-1 and/or u-PAR) on hepatocytes (110), while t-PA and t-PA-
PAI-1 complexes have been shown to be cleared by LRP1 (on hepatocytes and Kupffer cells) 
and the mannose receptor (on endothelial cells) (110, 112, 113). 
 
 
Figure 4. Relationships and effects of plasmin in fibrinolysis and in hepatic homeostasis. Plasmin is a 
multi-functional serine protease that promotes dissolution of fibrin clots during hemostasis. It is activated by 
urokinase plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA) and inhibited by α2-
antiplasmin and α2-macroglobulin. Adapted from (100). 
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Each of the members of the PAS has known non-classical functions. Plasmin has been 
reported to cleave a variety of extracellular matrix proteins, growth factors, and proteases. For 
instance, the activation of matrix metalloproteinase (MMP)-2 and -9, both targets of 
plasminogen-mediated proteolysis, is essential for successful tissue remodeling in normal liver 
regeneration (95). Through binding to its cell-surface receptor u-PAR (urokinase plasiminogen 
activator receptor), u-PA mediates cell-mediated matrix turnover and cell migration (114). t-PA 
has emerged as a regulator of the blood-brain barrier via ligand-binding to LRP1 (115). The PAs 
and plasmin have also been noted to activate hepatocyte growth factor (HGF), the biological 
importance of which is discussed in greater detail below. 
 
 
Figure 5. Schematic illustrating the different functional domains of t-PA. t-PA is a bi-functional protein, with 
N-terminal receptor and fibrinogen-binding regions and a C-terminal protease domain.  
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1.3.2 Plasminogen activators in liver homeostasis 
Plasminogen is primarily expressed in the liver. The resting liver does not express detectable 
amounts of the PAs or PAI-1; however, studies in rodents have revealed multi-dimensional roles 
of the PAS in normal liver repair after injury, as shown in Figure 6. The generation of plasmin by 
the PAs is necessary for appropriate clearance of fibrin and restoration of normal liver 
architecture following acute liver injury (116). Mice lacking plasminogen have prolonged liver 
injury and fibrin deposition after acute carbon tetrachloride intoxication despite normal 
hepatocyte proliferative response post-injury (117). Interestingly, however, plasminogen-
dependent tissue remodeling is not rescued by concurrent genetic deletion of fibrinogen. 
Correspondingly, genetic loss of u-PA or both u-PA and t-PA in mice prolongs liver injury and 
fibrin deposition compared to wild-type controls (116, 118, 119).  As noted above, the PAs and 
plasminogen have also been shown in vitro and in vivo to be indirect and direct activators of 
HGF, a prominent hepatocyte mitogen and anti-apoptotic factor that signals through the tyrosine 
kinase receptor MET (120-123).  In fact, constitutively active MET is able to rescue 
plasminogen-null mice from an inability to reorganize liver architecture (120). These studies 
demonstrate the integral, although not completely understood, role of plasmin activity in 
promoting resolution of liver injury.  
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Figure 6. The plasminogen activators promote liver homeostasis. After injury, the plasminogen activating 
system has multi-functional roles in promotion of matrix turnover via plasmin activation and fibrin clearance 
during injury and activating growth factors such as hepatocyte growth factor (HGF). Adapted from (100). 
 
1.3.3 Plasminogen activators in liver injury and fibrosis 
Evidence for a role for the PAs in modulating human liver cirrhosis is not lacking. In a study 
examining the prevalence of pro-thrombotic risk factors in a cohort of chronic hepatitis patients 
segregated by histologic severity of fibrosis, plasminogen deficiency (as measured by 
colormetric assay of patient plasma) was present in 19% of patients with advanced fibrosis 
versus 2% in mild fibrosis (p=0.03) (124). Our laboratory reported elevation of plasmin protein 
levels in human cirrhotic livers as compared to normal control tissues (125). Interestingly, in the 
same study, hepatocellular carcinomas were generally plasmin negative. Elevation of tissue 
expression and serum concentration of the PAs and their targets (HGF, plasmin) have been 
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observed in chronic liver injury and disease in humans and rodents but is accompanied by 
increases in PAI-1 (125-127). This suggests a net decrease in PA and plasmin activity, despite 
increased concentrations, may contribute to liver fibrosis.  
HSCs regulate plasminogen activation through expression of various components of the 
PA system, such as u-PA and PAI-1 (128). In addition, exogenous plasmin can suppress in vitro 
activation of HSCs.  Martinez-Rizo et al. found that by over expressing u-PA in a human-derived 
HSC line and increasing plasminogen activation, they could suppress HSC activation and 
expression of pro-fibrotic cytokines such as TGF-β1 in a plasmin-dependent manner (129).   
In animal studies, a decrease in HGF activation was seen after surgical resection in rats 
with dimethylnitrosamine-induced cirrhosis (130). Correspondingly, loss of PAI-1 ameliorates 
liver fibrosis development three weeks post-bile duct ligation and is associated with increases in 
t-PA activity and HGF activation (131). A recent study using a lung fibrosis model also 
demonstrates that loss of PAI-1 leads to increased HGF activation and downstream production of 
prostaglandin E2, a known anti-fibrotic factor in lung (132).  Hence, it is reasonable to 
hypothesize that the concurrent increase in PAI-1 expression in liver fibrosis models inhibits 
HGF activation and exacerbates liver injury. 
Conversely, over-expression of components of the PAs can reverse liver fibrosis in vivo. 
HGF gene therapy, when given as a naked DNA plasmid by tail vein injection or by 
intramuscular injection, can improve cirrhosis by either bile duct ligation or carbon tetrachloride 
(91, 133). PA gene therapy can improve liver cirrhosis as well; a single dose of uPA, introduced 
by adenoviral vector to rats after six weeks of carbon tetrachloride administration, led to marked 
histological improvement by 10 days post-therapy. Reduction of fibrosis was associated with 
increased HGF transcription and MMP-2 activity (134). 
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Nevertheless, a relevant signaling role of the PAs during liver fibrogenesis remains 
unclear.  Higazi et al. recently reported amelioration of fibrosis with the loss of either or both of 
the PAs (135), while Hsiao and colleagues reported exacerbation of hepatic fibrosis with the loss 
of t-PA (136).  Interestingly, in a model of in vivo alcoholic injury, plasminogen activation was 
promoted at moderate dosage of alcohol (0.4 g/kg) but suppressed at higher dosages due to an 
increase in PAI-1 activity. Furthermore, in vitro treatment of a human stellate cell line with a low 
concentration of alcohol (10 mM) increased plasmin activity, and this effect was dependent on 
the receptor annexin A2, a plasminogen and t-PA receptor (137). Taken together, it is likely that 
the PAs have signaling roles that are relevant in liver fibrosis development; however, any study 
that wishes to analyze the mechanisms must remember to take into account the relative levels of 
the PA and plasmin inhibitors. 
1.4 LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1 (LRP1) 
1.4.1 General structure and function 
LRP1 (also commonly known as α2MR and CD91) is a 600 kDa multi-functional receptor that 
binds to over 40 different ligands (138). These include ligands such as lipoproteins (e.g. LDL, 
VLDL), proteases and their inhibitor complexes (e.g. t-PA/PAI-1, α2-macroglobulin, 
metalloproteinases), and growth factors (e.g. TGF-β1, CTGF). In addition to functioning as a 
clearance receptor to control serum concentrations of these diverse ligands, LRP1 plays cell-
specific roles in normal and pathologic physiology (139); it has been found to be involved in 
blood-brain barrier permeability (140), regulation of β-amyloid generation in the brain (141), 
 23 
cancer cell survival and metastasis (142), and atherosclerosis development (143). LRP1 null 
mice are embryonic lethal due to dysregulation of uPA:PAI-1 complexes at the site of 
implantation (144).  
LRP1 is composed of two chains: the α-chain is 515 kDa, completely extracellular, and 
contains the ligand-binding regions, while the β-chain is 85 kDa and contains the transmembrane 
and intracellular tail portions of the molecule (145), as indicated in Figure 7. They are 
synthesized as one chain, cleaved, and remain associated with each other non-covalently. The 
cytoplasmic tail contains two NPXY motifs that are sites of phosphorylation and adaptor protein 
docking (146). Additional phosphorylation sites are involved in regulating endocytosis and 
recycling of the receptor (147). LRP1 can be phosphorylated by kinases such as v-Src, inducing 
binding of docking proteins including Shc and Disabled-1 (148, 149). Its activity is regulated 
endogenously by the chaperone protein RAP (receptor-associated protein), which binds to it 
during processing in the endoplasmic reticulum and Golgi apparatus to prevent intracellular 
activation of the receptor (150). Proteolytic cleavage at an extracellular membrane-proximal 
region can mediate release of the extracellular domain as a soluble receptor (151), while 
intracellular cleavage of the cytoplasmic tail domain by γ-secretase-like activity releases a 
potential intracellular signaling molecule (152). 
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Figure 7. Schematic of LRP1 and ligand-binding regions. The plasminogen activators and its 
inhibitor can bind to multiple regions on the LRP1 receptor. Adapted from (153). 
 
 
1.4.2 t-PA and LRP1 in kidney fibrosis 
Recent studies have defined a non-proteolytic role for t-PA in the development of kidney 
fibrosis.  Mice lacking t-PA developed significantly less tubular injury and matrix deposition in a 
model of unilateral urethral obstruction (UUO) that correlated with decreased levels of MMP-9 
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but no change in plasmin expression and activity, suggesting that the activation of MMP-9 in 
wild-type mice via t-PA was independent of its proteolytic activity (154).  Further studies found 
that the previously characterized t-PA clearance receptor LRP1 was necessary for the induction 
of MMP-9 by t-PA (155). LRP1 becomes phosphorylated upon ligand-binding of t-PA, leading 
to myofibroblast differentiation of kidney tubular epithelial cells.  These signal transduction 
events are mediated through β1 integrin and integrin linked kinase (ILK) (156).  Furthermore, t-
PA signaling through LRP1 also promotes myofibroblast survival in the presence of apoptosis-
promoting conditions via ERK1/2 dependent mechanism (157). Hence, these data strongly 
support a non-proteolytic role for t-PA-mediated promotion of kidney fibrosis.  
1.4.3 Role of LRP1 in smooth muscle cells 
In contrast, LRP1 has been found to suppress the function of signaling pathways that are known 
to be involved in promoting fibrogenesis, such as the platelet derived growth factor receptor-β 
(PDGFRβ). Increased PDGF ligand binding promotes HSC proliferation and liver fibrosis (158, 
159), while inhibition of PDGFRβ signaling can decrease liver fibrosis (160). PDGFR signaling 
is also mitogenic in vascular smooth muscle cells (161) and contributes to development of 
atherosclerotic plaques (162). 
Recent studies have uncovered that LRP1 suppresses smooth muscle cell proliferation 
and is protective in a murine model of atherosclerosis (143). LRP1 null vascular smooth muscle 
cells had increased levels of PDGFRβ, increased markers of proliferation, and larger 
atherosclerotic plaque formation. Inhibition of PDGFRβ activation through use of imatinib 
(Gleevec) was able to decrease plaque formation in smooth muscle LRP1-null mouse aortas, 
suggesting that LRP1 is protective against atherosclerosis by suppressing PDGFRβ (or other 
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tyrosine kinase receptor) activity (143). Previous work demonstrated that LRP1 and PDGFRβ act 
as co-receptors: upon PDGF receptor-ligand interaction, LRP1 is phosphorylated in a PDGFRβ-
dependent manner and clusters with PDGFRβ within clathrin-coated pits for endocytosis (163, 
164). It is postulated that in this way, LRP1 targets PDGFRβ for degradation, and the loss of 
LRP1 then allows sustained surface expression of PDGFRβ, such as was seen in the smooth 
muscle cell-specific LRP1 knockout. 
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2.0  TISSUE-TYPE PLASMINOGEN ACTIVATOR DOWN-REGULATES HEPATIC 
STELLATE CELL ACTIVATION THROUGH LDLR-RELATED PROTEIN 1 IN RATS 
AND MICE 
2.1 INTRODUCTION 
Liver cirrhosis is a rapidly growing global health concern due to the increasing prevalence of 
chronic liver diseases such as viral hepatitis and non-alcoholic fatty liver disease. Regardless of 
etiology, chronic parenchymal injury leads to accumulation of scar tissue and organ dysfunction 
through a highly orchestrated process centered on a de novo population of myofibroblast-like 
(MFB-like) cells. Hepatic stellate cells (HSCs) are considered one of the major sources of 
matrix-depositing MFB-like cells in liver injury; in response to inflammatory cytokines and 
growth factors, they become more proliferative, migratory, contractile, and fibrogenic (7). 
Gaining greater understanding of the factors that regulate HSC trans-differentiation is key to 
selecting druggable anti-fibrotic targets. 
The plasminogen activators are multifunctional serine proteases involved in fibrinolysis, 
cellular migration (165), growth factor activation (166), and hepatic repair after injury (116, 
167). Loss of the plasminogen activators delays liver regeneration after acute injury, which has 
been largely attributed to sustained fibrin deposition and loss of growth factor and matrix 
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metalloproteinase activation (116). However, their roles in chronic liver injury have been 
ambiguous (135, 136), possibly due to pleiotropic functions on multiple cell types. 
Emerging literature suggests the biological effects of the plasminogen activators in any 
system cannot be isolated to their proteolytic function; in fact, signaling functions may be 
equally, if not more, important to understanding their roles in disease processes. In particular, 
tissue-type plasminogen activator (t-PA) is a key endogenous signaling molecule in injury and 
disease (156). One prominent t-PA signaling receptor is LRP1 (LDLR-related protein 1). LRP1 
is a multi-ligand receptor involved in protease-inhibitor complex and growth factor clearance, 
but additionally, it can signal following ligand-binding to promote cellular migration, 
differentiation, and changes in viability or proliferation (139). Recent studies have defined new 
roles for LRP1 in modulating tissue fibrosis and the myofibroblast phenotype (156). HSCs are 
now known to express LRP1 (168, 169); however, little is known about the role of LRP1 in 
HSCs during liver injury and regeneration.  
In the present study, we sought to establish if there is t-PA-mediated signaling through 
LRP1 in HSCs. We anticipated a pro-fibrotic response, similar to kidney; however, here, we 
present data demonstrating that LRP1 activation by t-PA in vitro decreases expression of 
markers associated with HSC activation. Further, in vivo deletion of LRP1 in HSCs, or t-PA 
globally, allows MFB-like cells to persist after injury. Hence, t-PA mediated signaling through 
LRP1 suppresses pro-fibrotic MFB-like cells, a finding with potential therapeutic value for 
chronic liver disease. 
 29 
2.2 EXPERIMENTAL PROCEDURES 
2.2.1 Reagents and Antibodies 
Recombinant single-chain and two-chain t-PA (American Diagnostica, Stanford, CT, and 
Molecular Innovations, Novi, MI) and an irreversible, inhibitor-treated, non-proteolytic form of 
t-PA (FPRCK-TPA, Molecular Innovations) were used for cell culture experiments. FPRCK-
TPA is tested to have zero enzymatic activity by functional assay (personal communication with 
company representative). Recombinant human TGF-β1 was purchased from R&D Systems 
(Minneapolis, MN) Antibodies used for immunohistolabeling and Western blotting include: α-
SMA (Clone 1A4; Dako, Carpinteria, CA or Sigma-Aldrich), p-LRP1 (Santa Cruz Biotechology, 
Santa Cruz, CA), LRP1 (Clone 11H4; ATCC, Manassas, VA or #3501; American Diagnostica), 
PDGFRβ (Santa Cruz), p-Akt (Thr308) and total Akt (both Cell Signaling Technology, Danvers, 
MA), p-ERK1/2 and total ERK1/2 (Cell Signaling Technology, t-PA (American Diagnostica), 
PAI-1 (American Diagnostica). The PI3K pathway inhibitor LY294002 was from Cell Signaling. 
Human RAP was prepared as described (170). 
2.2.2 Rat hepatic stellate cell isolation and cell culture 
Male Fischer 344 rats (Charles River, Wilmington, MA) greater than 200 grams in weight were 
used for isolation of primary HSCs. Primary rat HSCs were isolated using a protocol adapted 
from Riccalton-Banks, et al. (171). Briefly, liver cells of male Fischer 344 rats were dissociated 
using an in situ two-step collagenase perfusion method, as previously described (172, 173). After 
low-gravity centrifugation of total liver cell suspension in calcium-free buffer to isolate 
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hepatocytes, non-parenchymal cells were isolated from the resulting supernatants (174, 175). The 
NPC fraction was washed once in complete medium (Dulbecco’s Modified Eagle Medium + 
10% fetal bovine serum + 0.1% gentamicin solution) and plated on 3-4 uncoated six-well tissue-
culture plates. Cells were maintained in a humidified incubator at 37°C with 5% CO2. Complete 
medium was replaced 24 hours post-plating. At 48 hours post-plating, cells were serum starved 
for 24 hours before treatment as indicated in the text. Rat HSC-T6 and human LX-2 cells (both 
gifts from Dr. Scott Friedman, Mt. Sinai School of Medicine, New York, NY) maintained in the 
same medium as primary HSCs were used for t-PA experiments. HSC-T6 cells were seeded at 
3x10
5
 cells/mL, allowed to attach overnight, then serum starved for 24 hours prior to treatment 
as indicated. LX-2 cells were seeded at 1x10
5
 cells/mL and allowed to grow to ~60% confluency 
prior to serum starvation and subsequent treatment. NRK-49F cells (ATCC) were cultured in 
Dulbecco’s modified Eagle’s medium/Ham’s F12 (1:1) supplemented with 5% FBS until ~70% 
confluency, after which cells were serum starved 24 hours prior to treatments as indicated in text. 
2.2.3 MTT and [3H]Thymidine Incorporation Assays 
HSC-T6 cells were seeded at 3x10
5
 cells/mL and allowed to attach overnight in complete 
medium. Cells were treated with vehicle control or t-PA (10nM) for 48 hours in serum-free 
conditions. An MTT-based in vitro toxicology assay kit (Sigma-Aldrich) was used according to 
manufacturer instructions to assess for mitochondrial dehydrogenase activity after 48 hours. For 
the [
3
H]thymidine incorporation assay, [
3
H]thymidine was added to the medium to a final 
concentration of 2.5 μCi/ml at the same time as t-PA treatment. After 48 hours, cells were fixed 
with ice-cold 5% trichloroacetic acid, washed in running tap water, and air dried completely. 
One milliliter of 0.33N NaOH was added to each well for 30 minutes to solubilize the cells. A 
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300-μl aliquot from each well was used to measure cpm/dpm in a Beckman LS6000IC 
scintillation counter (Beckman Coulter, CA). 
2.2.4 SDS-PAGE and Western Blot 
Cell cultures were harvested in lysis buffer (10mM Tris buffer with 1% sodium dodecyl sulfate 
and protease/phosphatase inhibitor cocktail) and analyzed by Western blot as previously 
described in detail (121, 176). Briefly, thirty micrograms of protein from each sample was mixed 
with loading buffer with or without 100 mmol/L dithiothreitol, heated to 65°C for 15 minutes, 
resolved by electrophoresis on 8 or 10% SDS-polyacrylamide gels, and transferred to 
polyvinylidene difluoride membranes for western blot analyses. Membranes were blocked in 5% 
milk or fish gelatin in Tris-buffered saline + Tween, followed by incubation with primary 
antibody in 5% blocking buffer. Horseradish peroxidase-conjugated secondary antibodies 
(Jackson ImmunoResearch Laboratories, West Grove, PA) were used at a concentration of 
1:50,000. Blots were developed using enhanced chemiluminescence substrate (Pierce, Rockford, 
IL) and visualized on X-ray film. Loading equivalence was assessed from densitometry of 
scanned images of Ponceau Red staining performed immediately after transfer of protein onto 
the polyvinylidene difluoride membranes (97). 
For western blot analysis of cell culture medium post-treatment, 250 microliters of 
conditioned medium were supplemented with protease/phosphatase inhibitors and concentrated 
to approximately 20 microliter volume and applied to an 8 or 10% SDS- polyacrylamide gel for 
resolution. Transfer and blotting were preformed as described above. 
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2.2.5 Immunoprecipitation 
HSC-T6 cells were treated with vehicle control or t-PA for one minute and lysed in ice-cold 
CHAPS buffer (10 mM CHAPS, 20 mM HEPES [pH 7.4], 150 mM NaCl, 2 mM CaCl2) 
supplemented with phosphatase and protease inhibitor cocktails (Sigma-Aldrich). Samples were 
sonicated on ice to further homogenize the cells. One hundred micrograms of lysate from each 
treatment were incubated with mouse IgG and Protein A/G PLUS agarose beads (Santa Cruz 
Biotechnology Inc.) for an hour at 4°C to “pre-clear” the lysate. Beads were pelleted and 
supernatants transferred to new tubes. The pre-cleared lysates were then incubated with 
monoclonal antibody against LRP-1 (11H4) or equivalent amount of mouse IgG at 4°C overnight 
with rotation. Protein A/G PLUS agarose beads were added to the lysates and incubated at 4°C 
for 3 hours. The beads were pelleted, washed with CHAPS buffer, and the bound proteins were 
extracted from the beads in reducing sample buffer. Proteins were resolved on 10% SDS-
polyacrylamide gel, and analyzed by western blotting as described above, using anti-
phosphotyrosine (BD Biosciences, San Jose, CA) and anti–LRP-1 (11H4) antibodies.  
2.2.6 Reverse Transcription and Polymerase Chain Reaction 
Treated cells were harvested using RNABee (Amsbio, Lake Forest, CA)-chloroform extraction 
and precipitated with isopropanol. Isolated RNA was DNase-treated using Turbo DNase kit (Life 
Technologies, Grand Island, NY) according to manufacturer instructions. RNA was converted to 
cDNA using random hexamers and SuperScript III reverse transcriptase (Life Technologies). 
One hundred nanograms of cDNA from each sample were used for polymerase chain reaction for 
collagen Iα1 or β-actin. Primers used were previously described (177). The primer sequences 
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used were as follows: Collagen I Forward Primer 5’-AAC GGC AAG GTG TTG TGC CAT G-
3’; Collagen I Reverse Primer 5’-AGC TGG GGA GCA AAG TTT CCT C-3’; β-actin Forward 
Primer 5’-GAG CTA TGA GCT GCC TGA CG-3’; β-actin Reverse Primer 5’-GTG CTA GGA 
GCC AGG GCA GTA A-3’. No enzyme and water controls were run for each primer set (data 
not shown). PCR consisted of 30 cycles at 94°C for 1 minute, 57°C for 1 minute, and 72°C for 1 
minute, followed by a final extension step at 72°C for 7 minutes. PCR products were run on a 
2% agarose gel containing ethidium bromide and visualized with ultraviolet light for 
photography. 
2.2.7 Gene Array Analysis  
HSC-T6 cells were cultured and treated with vehicle control or t-PA for 24 hours as described 
above. Three treated wells from a six-well plate were pooled for each condition and cell pellets 
were snap-frozen until further preparation (as described below). A parallel plate was harvested 
for western blot analysis for α-SMA to confirm previously seen effects prior to proceeding with 
the microarray. All sample preparation and hybridization procedures were performed by the 
laboratory of Dr. Jianhua Luo in the Department of Pathology at the University of Pittsburgh 
School of Medicine. Double stranded cDNA was synthesized from total RNA and used as the 
template in vitro transcription to generate biotin-labeled cRNA according to manufacturer’s 
instructions. Eight micrograms of the labeled cRNA from each sample was fragmented and 
hybridized to Rat Genome 230 2.0 GeneChip array (Affymetrix, CA, USA) and the signal was 
amplified by biotin-avidin-phycoerythirn technique. Affymetrix scanner 3000 7G and Genechip 
Operating software 3.2 (Affymetrix, CA, USA) were applied to scan the images and convert 
intensity to a numerical format representing an average difference value for each probe.  Raw 
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data were analyzed by removing all probes with values having a combined sum of less than 200 
intensity units between the compared treatments. Unidentified sequences were excluded. The 
remaining data was sorted by both fold change and absolute change in intensity between 
treatments. 
2.2.8 Carbon tetrachloride acute injury and resolution experiments 
Male C57Bl/6 (Jackson Laboratories, Bar Harbor, Maine), t-PA -/- (Jackson 
Laboratories), or LRP
flox/flox
;SM22-cre +/- mice (Strickland laboratory, University of Maryland at 
Baltimore), aged 10-12 weeks, were used for in vivo acute liver injury experiments. Mice were 
given plain water or  0.05% phenobarbital (PB) water ad libitum for one week prior to corn oil 
(control) or carbon tetrachloride (CCl4) injections (1uL/gram body weight, diluted 1:4 with corn 
oil for injection; Sigma-Aldrich, St. Louis, MO). The PB equalized the cytochrome P450 enzyme 
2E1 expression by western blot amongst the different genotypes after injury (see Figure 16-17) 
(178). Two acute doses of CCl4 were given three days apart and mice were harvested over a time 
course of 1-14 days after the second dose. Total and liver body weights were recorded at time of 
sacrifice. Serum and liver tissue were collected for biochemical and histological analyses. Serum 
alanine transaminase was analyzed by the University of Pittsburgh Medical Center-Presbyterian 
Hospital, Department of Pathology Lab Support Services. 
2.2.9 Immunohistochemical staining and fluorescent labeling 
Formalin-fixed paraffin embedded livers from CCl4-treated mice (n=3-5 at each time 
point) were cut into 4µm-thick section for immunostaining. Immunohistochemistry was done by 
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standard avidin-biotin complex-horseradish peroxidase method. Double staining on paraffinized 
mouse tissue sections with anti-α-SMA (1:50) and anti-p-LRP1 (1:200) was labeled with Qdot-
conjugated anti-mouse Q705 and anti-rabbit Q605 antibodies, respectively (Life Technology). 
Triple staining was done with the addition of anti-t-PA (1:150) labeled with biotinylated anti-
goat secondary and Streptavidin-Q655. Anti-human α-SMA antibody was confirmed to cross-
react with mouse α-SMA and be specific to α-SMA with a mouse-on-mouse blocking kit (Vector 
Laboratories, Burlingame, CA). Sequential double labeling on LRP
flox/flox
;SM22-cre
 +/-
 mice and 
t-PA
-/- 
mice liver was done using Acetone:MeOH (1:1) fixed 4µm-thick frozen sections with 
anti-LRP1 (1:50, American Diagnostica) and anti-mouse-Cy5 secondary antibody, followed by 
αSMA-Cy3 (1:1000, Sigma-Aldrich). 
2.2.10 Image Capture and Analysis 
Provis microscopes for brightfield imaging (Olympus, Center Valley, PA), Olympus Fluoview 
1000 upright confocal microscopy for fluorescence imaging, and Metamorph software 
(Sunnyvale, CA) for quantification of staining were located in and provided by the Center of 
Biologic Imaging at University of Pittsburgh. For quantification of immunohistochemical stains, 
low-powered images were taken at regular intervals to cover as much of the stained tissue as 
possible in a non-discriminate fashion. Only edges, large vessel lumens, and artifacts were 
avoided in the image capture. Only slides that were stained together and imaged together were 
compared in analysis. Images were thresholded for positive staining and analyzed for area of 
staining using the same threshold. Qdot-labeled tissues were scanned with a Zeiss AxioVision 
MIRAX MIDI scanner (Carl-Zeiss, Jena, Germany) and captured single frame with the 
Pannoramic Viewer from 3DHISTECH (Budapest, Hungary).  
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2.2.11 Statistical Analysis 
Densitometry of scanned western blot and PCR gel images was analyzed using NIH ImageJ 
1.42q (National Institutes of Health, USA). For western blots, scanned images of Ponceau stain 
were used to normalize protein loading and transfer between samples (97). All graphing and 
statistical analysis was performed using Prism (GraphPad, La Jolla, CA) or Excel (Microsoft, 
Redmond, WA). When two groups were compared, Student’s t-test was performed. When more 
than two groups were compared, one-way analysis of variance test was performed with Tukey’s 
post-test analyses. Statistical significance was set at p<0.05, and variability within a group is 
presented as +/- standard error of the mean (SEM). 
2.2.12 Animal use approval 
The studies described were approved by the University of Pittsburgh Institutional Animal Care 
and Use Committee in accordance to the "Guide for the Care and Use of Laboratory Animals" 
published by the National Institutes of Health. The University of Pittsburgh is an accredited 
institution by the Association for Assessment and Accreditation of Laboratory Animal Care. 
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2.3 RESULTS 
2.3.1 Exogenous t-PA decreases markers of HSC activation in primary and transformed 
cells 
To examine the effect of t-PA on HSC phenotype, we treated primary or immortalized HSCs 
with t-PA or vehicle control for 24 hours under serum free conditions. A reproducible decrease 
in the HSC activation markers α-SMA and PDGFRβ was seen in t-PA treated cells compared to 
vehicle controls (Figure 8A). In addition, t-PA markedly decreased collagen I mRNA expression 
in primary rat HSCs after 24 hour treatment (Figure 8A). Lastly, we observed a significant loss 
of mitochondrial activity as assessed by the MTT assay, a surrogate marker of cell viability, and 
a corroborating trending decrease in 
3
[H]-thymidine incorporation in HSC-T6 cells after 48 hours 
treatment with t-PA (Figure 8B). Collectively, these data demonstrate that t-PA treatment is 
sufficient to suppress markers of HSC activation in vitro. 
Since our results in HSCs were in contrast to what was reported to be observed in kidney 
fibroblasts (156), we repeated the experiments reported in the literature with the NRK-49F cell 
line with our reagents. As seen in Figure 8C, a preliminary experiment with the NRK-49F cells 
confirms the increase in fibroblast activation by western blot analysis of α-SMA in whole cell 
lysates post-treatment with t-PA, either alone or in combination with TGF-β1. Thus, there are 
cell-specific effects of t-PA between fibrogenic cell types of different organs. 
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Figure 8. Exogenous t-PA suppresses HSC activation in vitro. (A) Primary rat stellate cells or cell lines (HSC-
T6, rat; LX-2, human) were cultured serum-free for 24 h and stimulated for another 24 h with t-PA (10 nM). 
Whole cell protein lysates or RNA were prepared, pooled, and equal amounts were subjected to western blot 
analyses or RT-PCR, respectively, for the indicated markers. Normalized densitometry values are given for 
representative images, relative to vehicle control, with loading normalized to total Ponceau staining/lane.  In 
all experiments, n=2-3 wells for 2-4 independent experiments per cell source. (B) HSC-T6 cells were 
stimulated with t-PA for 48h under serum-free conditions before measuring mitochondrial function (MTT 
reduction assay) or 
3
[H]-thymidine incorporation. n=3, *p<0.05. (C) For comparison, NRK-49F cells were 
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cultured to 70% confluency prior to serum starvation and 24 hour treatment with t-PA, TGF-β1, or both. 
Error bars are +/- SEM. (HSC, hepatic stellate cell; α-SMA, α-smooth muscle actin; PDGFRβ, platelet 
derived growth factor receptor-β; t-PA, tissue-type plasminogen activator; OD, optical density) 
 
2.3.2 Global gene expression changes after t-PA treatment of HSC-T6 cells 
To further understand the cellular effects of t-PA on HSCs, we treated the HSC-T6 cells with 
vehicle control or t-PA for 24 hours and harvested cells for microarray analysis of total cDNAs. 
Identifiable genes with the maximal changes after t-PA treatment based on fold change or 
absolute intensity change are presented in Tables 1 and 2, respectively. Of note, several genes 
involved in HSC activation were noted to decrease after t-PA treatment (α-SMA, -1.47 fold 
change; TIMP3, -2.15 fold; Vasopressin Receptor V1a, -3.0 fold; Serotonin receptor Type 1B, -
3.43 fold; Collagen III a1, -3062 total change; Collagen I a2, -2472.9 total; Collagen I a1, -1032; 
TIMP2, -966.7). Likewise, genes associated with HSC quiescence were up-regulated (nitric 
oxide synthase, +39.34 fold change; Retinol-binding protein, +2.84 fold change). These changes 
are consistent with the effects we reported in Figure 8 in HSC-T6 cells. 
2.3.3 The effects of t-PA on HSC activation are dependent on LRP1-mediated signaling 
Plasmin activity has been reported to have anti-fibrotic effects on HSCs (129). To assess the role 
of t-PA-mediated plasmin generation, we next asked whether the suppression of HSC activation 
markers by t-PA was dependent on its proteolytic activity. Interestingly, we see the same 
changes with treatment of a non-proteolytic form of t-PA (irreversibly inactivated) versus 
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wildtype t-PA (Figure 9A), suggesting in our in vitro system, t-PA’s effects are not plasmin-
dependent.  
t-PA is also a known signaling ligand for the receptor LRP1 (139). To see if LRP1 
becomes phosphorylated on HSCs in response to t-PA, we treated primary rat HSCs or 
immortalized HSC-T6 cells with t-PA for various lengths of time. LRP1 was selectively 
phosphorylated on the Tyr4507 residue within one minute of t-PA addition in HSC-T6 cells or 
five minutes in primary rat HSCs (Figure 9B). These same results were observed with the HSC-
T6 cells using immunoprecipitation of whole cell lysates with anti-LRP1 and then 
immunobloting for phospho-tyrosine (Figure 9B). 
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Figure 9. t-PA effects are protease-independent. Whole cell lysates were subjected to western blot with 
densitometry and loading values analyzed as in Figure 8 unless indicated otherwise. Representative images 
and matching values shown for A, B, C, and E. (A) Serum-free HSC-T6 cells were treated for 24 hours with 
recombinant human t-PA or protease-inactivated t-PA (irreversibly inhibited by the peptide ATA-FPR-
chloromethylketone). (B) HSC-T6 cells and primary rat HSCs were cultured serum-free for 24 h, stimulated 
for 1 or 5 min with t-PA, and lysates analyzed either by immunoprecipitation with anti-LRP1 antibody prior 
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to western blot analysis for phosphotyrosine, or directly probed with p-LRP1. In both situations, total LRP1 
was probed in parallel. (C-D) HSC-T6 cells were cultured serum-free for 24 h, pretreated with PI3K pathway 
inhibitor LY294002 or vehicle control (DMSO) for 60 minutes, and then treated with t-PA or t-PA vehicle in 
either DMSO or LY294002 for 10 minutes (C) or 24 hours (D). (E-F) Serum-free HSC-T6 cells were 
pretreated with the LRP1 inhibitor RAP or RAP vehicle control for 30 minutes, and then treated with t-PA 
or t-PA vehicle in the presence of RAP or RAP vehicle for 10 minutes (E) or 24 hours (F). n=6 and 3 for D 
and F, respectively.  Error bars shown are +/- SEM. **p<0.01. (HSC, hepatic stellate cell; t-PA, tissue-type 
plasminogen activator; CMK, chloromethylketone; LRP1, low density lipoprotein receptor-related protein 1; 
RAP, receptor-associated protein; α-SMA, α-smooth muscle actin; PDGFRβ, platelet derived growth factor 
receptor-β; DMSO, dimethyl sulfoxide; PI3K, phosphoinositide 3-kinase) 
 
 
Since Tyr4507 phosphorylation is essential for LRP1-dependent signaling pathway 
activation (146, 179), we tested whether t-PA addition had effects on known LRP1 downstream 
signaling targets. Akt was activated in t-PA treated HSC-T6 cells within ten minutes post-
treatment, and this effect was abolished in the presence of a PI3K/Akt pathway inhibitor, 
LY294002 (Figure 9C). Stimulation of HSC-T6 cells with t-PA in the presence of the LY294002 
inhibitor abrogated the suppression of α-SMA (Figure 9D). Comparable results were obtained 
using primary rat HSCs in a preliminary experiment (data not shown). 
To confirm that Akt signaling is dependent on activation of LRP1, we used an inhibitor 
of LRP1 ligand-binding, the chaperone protein RAP (receptor-associated protein), to prevent t-
PA signaling (180). Pretreatment with RAP in HSC-T6 cultures abrogated both Akt 
phosphorylation (Figure 9E) and the subsequent suppression of α-SMA expression (Figure 9F). 
In summary, LRP1-mediated signaling through Akt was sufficient to account for the observed 
effects of t-PA in HSCs. 
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We also observed transient ERK activation after treatment with t-PA in HSC-T6 cells 
(Figure 10); however consistent results were not obtained using MEK inhibitors, leading us to 
conclude that ERK activation was incidental rather than necessary for the downstream effects of 
t-PA-mediated signaling. 
 
 
 
Figure 10. Transient activation of ERK by t-PA in HSC-T6 cells. HSC-T6 cells were cultured serum-
free for 24 hours and stimulated with t-PA for 5-30 minutes. Whole cell lysates were analyzed by western blot 
for p-ERK1/2 and total ERK1/2. 
  
2.3.4 p-LRP1 and t-PA co-localization with α-SMA precedes resolution of injury in WT 
mice 
Since our in vitro data suggested that LRP1 signaling suppresses or reverses MFB-like 
differentiation, we hypothesized phosphorylation of LRP1 should occur on MFB-like cells just 
prior to their regression during resolution of an acute, in vivo hepatic injury.  WT mice were 
subject to acute liver injury by carbon tetrachloride (CCl4) following phenobarbital initiation and 
allowed to recover for up to 14 days in order to detect the time frame of injury resolution with 
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regard to the α-SMA+ cell population (please refer to Chapter 3.3.2 for more detailed description 
and justification of injury protocol used). As shown in Figure 11A, the α-SMA+ population 
drops off significantly between days four and five after injury. We next performed co-
immunolocalization of p-LRP1 and α-SMA spanning the same time points (Figure 11B). 
Strikingly, at day 4 there was little to no co-localization of p-LRP1 with α-SMA when the overall 
area of α-SMA-positive staining in the tissue was high; however, beginning at day five and 
throughout the rest of the recovery period, co-localization was readily observed, correlating with 
the loss of α-SMA immunoreactivity. Figure 11B highlights α-SMA+ regions not exclusive to 
vessels in order to focus on true de novo MFB-like α-SMA+ cells, rather than vascular smooth 
muscle α-SMA+ cells, indicating LRP1 is activated on α-SMA+ MFB-like cells when they 
regress from the tissue.  
Finally, we sought to verify that t-PA localized to SMA+ cells with activated LRP1. 
Liver sections from WT mice were co-immunolabeled at day four of recovery with antibodies 
against t-PA, p-LRP1, and α-SMA. Although sparse, we were able to find regions where all three 
were co-localized (arrow, Figure 11C) as well as multiple regions with t-PA adjacent to α-SMA+ 
cells (arrowheads, Figure 11C), indicating in situ proximity and interaction of t-PA with MFB-
like cells at a time point prior to increased p-LRP1 (day five; Figure 11B). These data support 
endogenous t-PA-LRP1 interactions on MFB-like cells during liver injury resolution. 
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Figure 11. LRP1 is activated on HSCs during resolution of acute hepatic injury in vivo. Wildtype 
(C57Bl/6) mice were given phenobarbital (PB) in water for one week and then intraperitoneally injected twice 
with CCL4 (1 uL/g body weight) at days 7 and 10 post-PB induction. Livers were harvested at days 2-7 and 14 
after the last dose, embedded in paraffin, and immunostained as indicated.  n=3 mice, days 2-7, n=2 mice, day 
14. (A) Metamorph software was used to quantify thresholded area of positive α-SMA staining of the entire 
image (10X images, minimum 10) to determine the timing of injury resolution in this model.  *p<0.05 using 
one-way ANOVA with post-test comparisons; only sequential differences denoted. Error bars shown are +/- 
SEM. (B) Immunofluorescent staining with Qdots was used to determine the timing of co-localization 
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between p-LRP1 and α-SMA (arrows). Representative images of standard α-SMA immunohistochemistry are 
shown in the top panels. Bottom panels represent higher magnifications of boxed regions from the middle 
panel. Days are post final CCL4 injection. (C) Qdots were used to determine if α-SMA, t-PA, and p-LRP1 co-
localize on day 4. Channels are separated from the same image to allow for comparison. Arrow indicates 
triple co-location, arrowheads indicate regions of α-SMA/t-PA co-localization. Scale bars 20 mm. (α-SMA, α-
smooth muscle actin; PB, Phenobarbital; CCl4, carbon tetrachloride; LRP1, low density lipoprotein receptor-
related protein 1) 
  
2.3.5 t-PA- and LRP1-deficient mice retain more α-SMA-positive cells after injury 
To clarify the role of t-PA signaling in vivo, we next compared t-PA null mice (181) to their 
corresponding controls after acute CCl4 liver injury to assess if regression of MFB-like cells is 
impaired. Following acute injury, there are no significant differences in the extent of 
parenchymal injury between WT and t-PA null mice in our model, as measured by serum ALT 
concentrations (Figure 12A). Nevertheless, t-PA null mice have significantly increased 
liver/body ratio at day six of recovery (Figure 12B) and significantly larger areas of α-SMA 
positive staining per visual field compared to WT mice, beginning at day five (Figure 12B), 
demonstrating a lag in injury resolution and MFB-like cell regression.  
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Figure 12. t-PA contributes to resolution of acute hepatic injury in mice. WT (C57Bl/6) and t-PA null mice 
(KO) were treated as described in Figure 11. Liver tissue and serum were collected at days 2-7 and day 14 
after the last dose. n=3-5 animals per time point for each genotype. (A) Comparison of the liver injury 
marker ALT in WT and t-PA null mice at the indicated time points after injury. No values were significant. 
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(B) Body to liver weight ratios were calculated and expressed as a percentage. WT and t-PA null mice were 
compared at baseline and prior to CCL4 injection, as well as throughout recovery after acute injury. Only at 
day 6 is there a significant difference seen. *p<0.05 (C) Metamorph software (20X images, minimum 
10/animal) was used to determine differences in α-SMA staining  in WT and t-PA  null mice. Days indicated 
are days after the last CCL4  injection. All error bars shown are +/- SEM. WT and KO groups were 
compared at each time point using Student’s t-test. n shown is number of mice analyzed.  **p<0.01, 
***p<0.001 as compared to WT. Sections from WT and KO mice on matching days were stained, imaged, 
and analyzed together. (t-PA, tissue-type plasminogen activator; WT, wildtype; KO, knockout; ALT, alanine 
transaminase; α-SMA, α-smooth muscle actin) 
 
 
As t-PA is globally inactivated in the t-PA null mice, we next tested whether the 
differences seen involved signaling in HSCs by repeating the experiment using conditional LRP1 
knockout mice (143). SM22, also known as transgelin, is a smooth muscle cell marker that is 
also selectively expressed in quiescent and activated stellate cells of the liver (182). Hence, 
amongst the different liver cell types, LRP
flox/flox
;SM22-Cre+
 
animals should selectively delete 
LRP1 from their stellate cells. To confirm loss of LRP1, we performed double immunolabeling 
of LRP1 and α-SMA on cryosections.  A decrease in co-localized signal relative to total SMA 
signal was seen in the LRP
flox/flox
;SM22-Cre+ (KO) mice at day four after injury as compared to 
the controls (WT; Figure 13A) when we compared equivalent areas of α-SMA+ staining. These 
mice were subjected to the same acute injury protocol and sacrificed at days four and six after 
injury. Similar to the t-PA null mice, the LRP1 conditional KO mice harbored more α-SMA+ 
cells than the control mice during recovery, despite a similar degree of liver injury (Figure 13B-
C). In summary, general loss of t-PA and targeted loss of LRP1 function delayed MFB-like cell 
resolution in vivo. 
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Figure 13. HSC LRP1 contributes to resolution of acute hepatic injury in mice. LRP
flox/flox
 (WT) and 
LRP
flox/flox
;SM22-Cre
+
 (KO) mice treated as described in Figure 11. Liver tissue and serum were collected at 
days 4 and 6 after the last dose. n=3 animals for each time point and genotype. (A) Representative confocal 
images of double immunolabeling with anti-LRP1 and anti-α-SMA antibodies of sections from Day 4 post-
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injury. Average co-localized signal as a percentage of total α-SMA staining is indicated for each genotype. 
Scale bar represents 50 mm. (B-C) Comparison between WT and LRP1 KO mice for serum liver injury 
marker ALT and staining quantification for percent area of positive staining for α-SMA (both as described in 
Figure 12) at the indicated time points after injury. Days indicated are days after the last CCL4 injection. 
Sections from WT and KO mice on matching days were stained, imaged, and analyzed together. Error bars 
shown are +/- SEM. groups were compared at each time point using Student’s t-test. **p<0.01, ***p<0.001 as 
compared to WT. (HSC, hepatic stellate cell; LRP1, low density lipoprotein receptor-related protein 1; α-
SMA, α-smooth muscle actin; ALT, alanine transaminase; WT, wildtype; KO, knockout) 
 
2.4 DISCUSSION 
Development of anti-fibrotic therapies to treat hepatic fibrosis/cirrhosis has the potential to 
decrease morbidity and mortality of patients with chronic liver diseases (183) and reduce their 
risk for hepatocellular carcinoma (184). HSCs play a crucial role in liver fibrogenesis; their 
depletion leads to marked amerlioration of fibrogenesis and tissue expression of markers of 
MFB-like cells after chronic liver injury (185). This study identifies non-proteolytic t-PA and its 
interaction with LRP1 as a possible therapeutic target for this disease.   
In liver, LRP1 has historically been known solely as a hepatocellular clearance receptor 
for t-PA (186). Our findings, that LRP1 on HSCs can bind to t-PA and exert other biological 
effects, expand this observation. A recent in vitro study used LRP1 inactivation to demonstrate 
that anti-proliferative and anti-migratory functions are mediated by LRP1 in HSCs (169). Our 
data adds to this knowledge by 1) identifying t-PA as a signaling ligand for LRP1, 2) associating 
in vitro changes with phenotypic transformation and, 3) confirming the phenotypic effects of 
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LRP1-mediated signaling in vivo.  Further, our finding that t-PA-mediated signaling through 
LRP1 can decrease, rather than increase, markers of activation in an Akt-dependent manner 
(Figure 9) opens up a greater question about what proteins partner with LRP1 to exert its 
functions. Although t-PA-mediated signaling through LRP1 on hepatic MFB-like cells in the 
present studies was anti-fibrotic, we observed the exact opposite outcome in a model of kidney 
fibrosis, where t-PA-mediated signaling through LRP1 was profibrotic (156).  LRP1 is a known 
co-receptor with proteins such as integrins (156), PDGFRs (187), and other tyrosine kinase 
receptors (188). In kidney, LRP1 and β1 integrin form a complex that then signals in a pro-
fibrotic manner through ERK. Our own preliminary experiments do not support a role for β1 
integrin in LRP1-mediated HSC signaling (data not shown); however, interestingly, constitutive 
loss of LRP1 in HSCs can induce ERK activity (169). Although we see transient ERK activation 
(Figure 10), MEK inhibitors did not yield the same effects as our results with RAP or the 
PI3K/Akt inhibitor (Figure 9). This suggests that signaling through ERK is also pro-fibrotic in 
HSCs and further supports the hypothesis that cell-specific partners of LRP1 may differentially 
regulate the divergent outcomes. Notably, our studies found that PDGFRβ was decreased upon 
activation of LRP1 through ligand binding by t-PA (Figure 8).  Hence, similar to vascular 
smooth muscle cells, in HSCs, LRP1 may partner with PDGFRβ and repress proliferation (143). 
Further studies will be needed to fully clarify the mechanism controlling LRP1 signaling in 
HSCs before therapeutic targeting can be implemented. 
Other studies have examined the effects of the plasminogen activating system (t-PA 
and/or the urokinase-type plasminogen activator, u-PA) on the resolution of acute liver injury; 
however, the studies primarily focused on the proteolytic actions of u-PA and t-PA with respect 
to plasmin generation and subsequent fibrin clearance.  Although u-PA and t-PA are commonly 
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believed to substitute for each other in regard to plasmin generation, with t-PA playing the 
dominant role, liver appears to provide the exception to this rule.  WT mice completely restore 
hepatocellular organization and fibrin clearance by day seven after injury; however, although t-
PA null mice only exhibit a mild defect in their repair, u-PA null mice show a severe delay in 
resolving hepatic injury with notable fibrin deposition (116). These data suggest that u-PA, 
rather than t-PA, is responsible for the majority of plasminogen activation and fibrin clearance in 
recovering liver tissue. Further, other studies also support a role for u-PA in generating hepatic 
plasmin both specifically in HSCs (118, 129) and in general (118, 129).  Interestingly, the 
plasmin generated by the HSC u-PA also appears to act in an anti-fibrotic manner (118, 129).  
Never the less, as our studies show that a proteolytically inactive t-PA can effectively generate 
MFB-like regression, we propose that the primary role of t-PA in liver repair is to signal in 
HSCs, rather than generate plasmin. 
Finally, it is worth noting that the function of t-PA in chronic liver injury still remains 
unclear; two separate studies tested t-PA null mice in CCl4 fibrosis protocols and reported 
opposite results (135, 136).  Interestingly, it was the longer study (6, versus 4, weeks of CCl4) 
that reported less fibrosis in the t-PA null animals as compared to their WT counterparts, despite 
an overall increase in liver damage and necrosis.  This suggests that extended insults to the liver 
invoke important changes in the microenvironment that can alter the outcome.  Importantly, with 
regard to the present work, neither of the chronic studies examined activation of LRP1 on HSCs, 
nor did they look at the ability of the t-PA null animals to resolve fibrosis after removing the 
injury. As the evidence presented here gives indication that exploiting the function of LRP1 on 
HSCs can protect from and maybe even reverse cirrhosis development, extending these studies to 
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chronic models is necessary if we are to explore the use of t-PA, an FDA-approved drug, for 
liver-targeted therapy for the resolution of liver injury and fibrosis prevention. 
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3.0  FURTHER INSIGHTS INTO TISSUE-TYPE PLASMINOGEN ACTIVATOR 
FUNCTION IN LIVER AND LIVER INJURY 
3.1 INTRODUCTION 
With the recent discoveries of LRP1-mediated signaling in many cell types, it is possible that the 
effects of exogenous t-PA on liver repair reported in Chapter 2 may not solely be due to LRP1 on 
HSCs. Of note, hepatocytes and Kupffer cells also are known to express LRP1 (110). In this 
chapter, we present intriguing data that support the idea that t-PA (via signaling through LRP1) 
may be exerting cellular effects on both hepatocytes and Kupffer cells after injury.  
Finally, our ultimate question is whether t-PA exerts an anti-fibrotic effect in the context 
of chronic injury. Previous chronic injury studies on t-PA null mice were conflicting (135, 136), 
but to extend the acute injury observations in t-PA null mice to a chronic injury model, we 
hypothesized that t-PA null mice would repair and resolve fibrosis at a slower rate than their 
wildtype counterparts. In this chapter, we present preliminary evidence to support this hypothesis 
in our model of chronic liver injury. 
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3.2 EXPERIMENTAL PROCEDURES 
3.2.1 Carbon tetrachloride chronic injury and resolution 
Male C57Bl/6 (Jackson Laboratories, Bar Harbor, Maine) or t-PA -/- (Jackson Laboratories) 
mice, aged 10-12 weeks, were given water or 0.05% phenobarbital water ad libitum for one week 
prior to corn oil (control) or carbon tetrachloride (CCl4) injections (1uL/gram body weight, 
diluted 1:4 with corn oil for injection; Sigma-Aldrich, St. Louis, MO). For acute injury, two 
doses of CCl4 were given three days apart and mice were harvested over a time course of 1-14 
days after the second dose. For chronic studies, mice were injected twice weekly 
(Friday/Monday injection schedule) for four weeks and were harvested at days 3 and 14 after the 
final injection (Figure 14). Serum and liver tissue were collected for biochemical and histological 
analyses.  
 
 
Figure 14. Schematic of chronic CCl4 administration in mice. Mice are given twice weekly 
intraperitoneal injections at a dose of 1 μL/gram body weight. After four weeks, mice are sacrificed at day 3 
to get a baseline reading of fibrosis development and at day 14 to assess rate of fibrosis resolution. 
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3.2.2 SDS-PAGE and western blot from liver tissue 
Frozen liver tissue was prepared for non-detergent fractionation, SDS-PAGE, and western blot 
analysis as previously described in detail (121, 176). Briefly, snap-frozen livers were pulverized 
on dry ice and homogenized in non-detergent lysis buffer (10mM Tris buffer, pH 7.6, 
supplemented with protease/phosphatase inhibitors P8340, P2714, P2850, P5726, AEBSF, and 
sodium amiloride [all from Sigma-Aldrich]). Homogenates were centrifuged at maximum speed 
in a chilled microcentrifuge (>14,000 x g). Supernatants were transferred to new tubes and 
designated as the cytoplasmic fraction, while the pellet was sonicated in additional Tris + 
inhibitors buffer with 1% SDS and designated as the cellular membrane compartment. Protein 
concentrations for both sets of samples were measured using the bicinchoninic acid assay 
(Pierce). Thirty micrograms of protein from each sample was mixed with loading buffer with or 
without 100 mmol/L dithiothreitol, heated to 65°C for 15 minutes, resolved by electrophoresis on 
8 or 10% SDS-polyacrylamide gels, and transferred to polyvinylidene difluoride membranes for 
western blot analyses. Membranes were blocked in 5% milk or fish gelatin in Tris-buffered 
saline + Tween, followed by incubation with primary antibody in 5% blocking buffer. Rabbit 
anti-CYP2E1 antibody (Abcam) was used at a concentration of at least 1:2500. Horseradish 
peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West 
Grove, PA) were used at a concentration of 1:50,000. Blots were developed using enhanced 
chemiluminescence substrate (Pierce, Rockford, IL) and visualized on X-ray film. Loading 
equivalence was assessed from densitometry of scanned images of Ponceau Red staining 
performed immediately after transfer of protein onto the polyvinylidene difluoride membranes. 
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3.2.3 Immunohistochemical staining and image capture 
Formalin-fixed paraffin embedded livers from CCl4-treated mice (n=3-5 at each time point) were 
cut into 4µm-thick section for immunostaining and routine H&E staining. 
Immunohistochemistry was done by standard avidin-biotin complex-horseradish peroxidase 
method. The following primary antibodies were used: mouse anti-α-SMA (1:50; Dako), rat anti-
F4/80 (1:50; Abcam), rabbit anti-collagen I (1:100; Abcam), and goat anti-t-PA (1:200; 
American Diagnostica). Species-appropriate biotinylated secondary antibodies were used 
(Millipore). 
Provis microscopes for brightfield imaging (Olympus, Center Valley, PA) and 
Metamorph software (Sunnyvale, CA) for quantification of staining were located in and provided 
by the Center of Biologic Imaging at University of Pittsburgh. Imaging and analysis were 
performed as described in Chapter 2. 
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3.3 RESULTS 
3.3.1 Increased macrophage populations in t-PA null mice after injury 
A recent study showed that t-PA is needed for integrin- and LRP1-mediated macrophage 
attachment during the process of migration to sites of injury (165). To investigate whether 
macrophage phenotype after injury could be affected, we performed immunohistochemical 
labeling for the macrophage marker F4/80 in tissues from wildtype and t-PA null mice at day one 
after acute injury, both with and without phenobarbital pre-treatment, and quantified the area of 
positive staining. Interestingly, more macrophages are seen in t-PA null mice liver tissue after 
injury (Figure 15), regardless of whether phenobarbital was administered (Figure 15B). It is 
unclear whether this is a baseline difference or induced only after injury; more studies are needed 
to understand the nature and implications of this phenomenon.  
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Figure 15. Increased macrophage numbers in t-PA null mice after injury. Wildtype (WT) and t-PA 
null (KO) mice were given 0.05% phenobarbital (PB) or plain water for one week and then intraperitoneally 
injected twice with CCL4 (1 μL/g body weight) at days 7 and 10 post-PB induction. Livers were harvested at 
day one after the last dose, embedded in paraffin, and immunostained with anti-F4/80 antibody.  n=4-5 mice. 
(A) Representative images of F4/80 immunostain for mice without PB treatment prior to CCL4. Scale bars 
indicate 100 μm.  (B) Metamorph software was used to quantify F4/80 staining (10X images, 6-11 images per 
genotype). *p<0.05, **p<0.01 using Student’s t-test. Error bars shown are +/- SEM. (CCl4, carbon 
tetrachloride) 
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3.3.2 Cytochrome P450 2E1 expression in WT and t-PA knockout mice 
Phenobarbital pre-treatment potentiates CCl4-induced liver injury by up-regulating the metabolic 
enzymes responsible for bioactivating CCl4 (189, 190). When considering the appropriate model 
for our acute liver injury experiments in t-PA knockouts (Figure 12), we first tested CCl4 injury 
with and without pretreatment of phenobarbital (0.05% in drinking water) in both wildtype and t-
PA knockout mice. We found that, in accordance to previous studies, phenobarbital-treated mice 
had a greater area of necrosis and injury than those mice not treated with phenobarbital. 
Correspondingly, MFB-like cell accumulation, as detected by α-SMA immunostaining, was 
increased in phenobarbital-treated mice (Figure 16A). Additionally, however, we discovered that 
there was a difference between the wildtype and t-PA knockout mice in extent of centrilobular 
necrosis and α-SMA+ staining (Figure 16A) in mice without pretreatment, while the 
phenobarbital-pretreated groups had no difference. So in addition to increasing the injury, the 
phenobarbital equalized the extent of injury between the two genotypes.  
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Figure 16. Phenobarbital pre-treatment equalizes CYP2E1 protein expression, CCl4-induced necrosis and 
HSC activation between wildtype and t-PA null mice. Wildtype (WT) and t-PA null (KO) mice were given 
0.05% phenobarbital (PB) or plain water for one week and then intraperitoneally injected twice with corn oil 
or CCL4 (1 μL/g body weight, diluted 1:4 in corn oil) at days 7 and 10 post-PB induction. Livers were 
harvested at day one after the last dose, embedded in paraffin, and immunostained with anti-α-SMA 
antibody or stained with H&E protocol.  (A) Representative images of H&E and α-SMA immunostain for 
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mice with and without PB treatment prior to corn oil or CCL4 injections. Images taken at 50X magnification. 
(B) CYP2E1 protein expression in membrane-enriched lysates from mice harvested at day one after acute 
injury. Ponceau stain is shown for respective blots to show equal protein loading. 
 
 
 
To further investigate the cause of this discrepancy, we first looked at the protein 
expression levels of the cytochrome P450 (CYP) 2E1 enzyme, the prominent bioactivator of 
CCl4, post-injury to see if there might be a difference in bioactivation (Figure 16B). At day one 
after acute injury, the wildtype mice without phenobarbital had down-regulated expression of 
CYP2E1 in response to CCl4, while the t-PA knockouts had sustained levels; phenobarbital pre-
treatment kept the wildtype expression elevated (Figure 16B). These results suggest differential 
regulation of CYP enzymes in t-PA null mice; however, the post-injury time point did not give 
us an understanding of whether differences existed between WT and t-PA null mice at time of 
injection, or whether the difference was in post-injury protein regulation. 
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Figure 17.  Baseline and post-phenobarbital protein expression of CYP2E1 in wildype and t-PA null 
mice. Membrane-enriched liver lysates were subjected to SDS-PAGE and western blot for CYP2E1 
expression for baseline and PB-treated mice, as indicated. Densitometry analysis of the two sets of samples is 
shown in lower panels, using Ponceau stain as a loading control. No differences were detected between the 
two genotypes in either condition. 
   
 
We then looked further at baseline levels of CYP2E1 to determine if differences in injury 
seen could potentially be due to inherent gene expression differences of CYP enzymes in t-PA 
null mice. CYP2E1, in contrast to post-injury, is not markedly different between wildtype and t-
PA knockout mice, with or without phenobarbital treatment (Figure 17).  
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3.3.3 Chronic injury studies in WT and t-PA deficient mice 
Since we observed a delay in resolution of MFB-like cells after acute injury in t-PA null mice 
compared to wildtype controls, we hypothesized that in chronic injury, more extracellular matrix 
deposition (i.e. fibrosis) would occur. To test this hypothesis, we expanded our acute injury 
model to a four-week chronic injury model (Figure 14) and sacrificed mice at day 3 and day 14 
after the last injection. We then immunostained liver tissue sections for collagen I deposition and 
compared the groups. At day three after the last injection, a baseline time point to measure the 
extent of fibrosis incurred after four weeks of injury, t-PA null mice had decreased average area 
of collagen I staining per visual field compared to wildtype control mice. However, by day 14 of 
recovery after the last injection, the t-PA null mice had significantly more collagen I still 
remaining in the tissue (Figure 18).  
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Figure 18. Increased collagen I deposition in t-PA null mice 14 days after cessation of chronic injury regimen. 
Wildtype (WT) and t-PA null (KO) mice were given 0.05% phenobarbital (PB) for one week and then 
intraperitoneally injected twice with CCL4 (1 μL/g body weight) twice weekly for four weeks. Livers were 
harvested at day 3 and 14 after the last dose, embedded in paraffin, and immunostained with anti-collagen I 
antibody. n= minimum 6 mice for each group. (A) Metamorph software was used to quantify area of 
thresholded positive collagen I staining from images taken across the entire usable tissue section (20X images, 
>10 images per animal). Error bars shown are +/- SEM. (B) Representative images for the collagen I staining 
is shown. Scale bar indicates 100 microns.  
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3.4 DISCUSSION 
The aggregate role of t-PA in liver homeostasis and repair is yet to be fully understood. It is 
likely that liver t-PA has multiple effects on many cell types. In Chapter 2, we describe a 
signaling role for t-PA on HSCs through the receptor LRP1. Here in Chapter 3, we describe 
differences in t-PA null mice that suggest roles with regard to macrophages (Figure 15) and 
hepatocytes (Figure 16-17) in addition to HSCs/MFB-like cells (Figure 18) during injury. 
Despite no differences in hepatocyte injury marker ALT between wildtype and t-PA null 
mice after CCl4 administration (Figure 12), another potential mechanism for sustained HSC 
activation in t-PA null mice during recovery, in addition to t-PA signaling loss on HSCs, could 
be changes in liver macrophage activation or population number. We find that t-PA null mice 
have increased accumulation of macrophages after injury (Figure 15). It has been reported that t-
PA contributes to macrophage migration in an integrin-dependent manner (165, 191). At this 
point, we have not investigated whether baseline numbers of macrophages are different in t-PA 
null mice; it is possible that the increased numbers reflect an inability of macrophages to undergo 
normal turnover or circulation. In addition, it is not clear whether cytokine production by t-PA 
null macrophages is altered.  
We have also demonstrated that CYP2E1 expression after acute liver injury is 
dysregulated in t-PA null mice (Figure 16). Hepatocytes are the cells that express CYP enzymes, 
thus the loss of t-PA in all cell types can affect hepatocyte behavior. Hepatocytes express LRP1 
and clear t-PA and t-PA:PAI-1 complexes from the blood (186). Although a signaling role has 
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yet to be attributed to t-PA on hepatocytes, it is possible that regulation of processes such as 
metabolism could be attributed to hepatocellular LRP1. Strategies to test this hypothesis will be 
discussed in the future directions (Chapter 4). 
Lastly, Figure 18 presents our first results in looking at the role of t-PA in chronic injury. 
We extended our acute injury out to four weeks (eight injections in total), and then looked at 
both the baseline fibrosis as well as the ability of the mice to resolve matrix deposition after 
injury is removed. Since two research groups have reported conflicting results about whether t-
PA promotes or protects from hepatic fibrosis (135, 136), we felt repeating the study was 
worthwhile and we felt that our injury model had distinct advantages: 1) we pretreated with 
phenobarbital to equalize the HSC activation initially as much as possible, 2) our CCl4 dose was 
stronger than the other two studies (1 μL/gram body weight compared to 0.5 μL/gram), 3) we 
looked at not only baseline but during recovery. Indeed, it seems that if anything, t-PA null mice 
are protected from fibrosis upon examination immediately after the chronic injury regimen. 
However, after two weeks of repair and recovery, the loss of t-PA renders the knockout mice 
unable to resolve matrix deposition in a timely manner (Figure 18). As collagen I deposition was 
an indirect measure of MFB-like cell accumulation and phenotype, further histochemical and 
biochemical studies need to be conducted to understand the mechanisms involved. These studies 
will be discussed in more detail in the future directions (Chapter 4). 
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4.0  GENERAL REMARKS 
4.1 SUMMARY 
Herein we present evidence to support a previously uninvestigated role for t-PA in liver: direct 
regulation of HSC phenotype and population, both in vitro and after acute injury in vivo. 
Exogenous t-PA is able to suppress markers of HSC activation in both immortalized HSC cell 
lines and primary rat HSCs (Figure 8). LRP1-mediated signaling is a necessary component of t-
PA’s actions on HSCs in vitro (Figure 9), and endogenous t-PA/LRP1 interactions occur during 
injury repair at time points congruent with the disappearance of MFB-like cells in vivo (Figure 
11).  Global loss of t-PA or HSC-specific loss of LRP1 delays regression of MFB-like cells after 
acute injury (Figures 12-13). Further, the rate of collagen I turnover is decreased in t-PA null 
mouse livers after chronic injury (Figure 18). Collectively, our data support an anti-fibrotic role 
for t-PA in liver that extends beyond its traditional plasminogen activating function. 
Additionally, we have discovered new attributes of t-PA null mice which merit further 
investigation. Differences in macrophage populations (Figure 15) and CYP2E1 protein 
expression (Figure 16-17) in t-PA null livers compared to control livers after acute CCl4 suggest 
that t-PA’s protective role in liver repair may also be due to effects on many cell types. 
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4.2 DISCUSSION AND FUTURE DIRECTIONS 
The overarching objective of this project was to determine the role of t-PA on HSC activation. 
Based on a substantial body of work done in collaboration with our laboratory that defines a pro-
fibrotic role for t-PA in kidney fibrosis (192), we first hypothesized that t-PA would promote 
HSC activation and liver injury. Indeed, as described above in detail, this did not end up being 
the case; in fact, we discovered that t-PA has exactly the opposite effect on HSCs but seemingly 
through the same mechanism of signaling, LRP1. However, although paradoxical, the results 
presented in this dissertation, in fact, are supported by many studies in liver that describe an 
overall protective role for plasminogen activators in liver repair. Genetic deficiency of 
plasminogen activators have been reported to aggravate liver repair in several injury models, 
including CCl4 and cholestatic injury (116, 167, 193). Our data add to these previous studies, but 
many questions still remain; these will be discussed below along with potential future directions 
for the project. 
4.2.1 Dissection of t-PA and LRP1 signaling partners in HSCs 
One of the foremost questions left unanswered by this work is the nature of LRP1 interactions on 
HSCs that distinguishes their response to t-PA from other fibroblasts, such as kidney fibroblasts. 
It is clear that a divergent set of roles for LRP1 exists, depending on the system. On one hand, 
our data in combination with the recent study by Llorente-Cortes et al. (169) describe an anti-
proliferative and deactivating effect on MFB-like cells. On the other hand, LRP1 on kidney 
fibroblasts promotes activation and proliferation (156, 157). 
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Therefore, our next step is to better elucidate LRP1 binding partners in HSCs. While we 
could test for many potential partners through co-immunoprecipitation followed by western blot, 
a large-scale approach may be more time and cost-effective due to the large number of described 
co-receptors and signaling molecules associated with LRP1. One way to achieve this is to 
perform co-immunoprecipitation studies using an anti-LRP1 antibody on HSC lysates at a time 
point when LRP1 phosphorylation and signaling activation has been established (between 1-10 
minutes, according to our findings presented here). This could be followed by mass spectrometry 
to identify all proteins pulled down in conjunction with LRP1 (194). Samples from HSCs that 
have been stimulated with t-PA can be compared with kidney fibroblasts similarly treated after 
confirming reproducibility of the divergent phenotypes at later time points (e.g. 24 hours) of cells 
treated in parallel. Another large scale approach might be to use widely-available 
phosphorylation immunoassay array kits or chips, in which a grid of different phospho-specific 
antibodies are affixed to a slide, allowing you to test activation of different signaling pathways in 
one sample at the same time.  
The intracellular signaling pathways downstream of LRP1 have only been partly 
elucidated. Originally characterized as the α2-macroglobulin receptor, a multi-functional protease 
inhibitor, it was shown that only the receptor-binding cleaved form of α2-macroglobulin could 
induce calcium influx and production of inositol phosphates and cyclic AMP (159). In Schwann 
cells, LRP1 and downstream ERK activation was required for selective gene induction by α2-
macroglobulin (158). Even with a classical LRP1 ligand such as α2-macroglobulin, however, 
there is still evidence for co-receptor requirement for its effects (159). 
Recent evidence suggests that the binding of the adapter protein Disabled 2 (Dab2) to the 
FXNPXY
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 may be key to the suppressive effects of LRP1; when Dab2 is displaced due to 
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mutagenesis of the receptor or loss of the receptor, there is a corresponding hyperactivation of 
ERK in CHO cells. As the cytoplasmic tail of LRP1 can bind to other adaptor proteins, it is 
likely that more thorough co-immunopreciptation studies described above, comparing t-PA 
treated cells of different origins will give insight into which co-receptors induce different adaptor 
proteins in response to t-PA.  
Another intriguing mechanism we have not fully studied is the role of t-PA:PAI-1 
complexes in signaling through LRP1. The inhibitor complex binds to LRP1 with more affinity 
than t-PA alone, and in many situations, PAI-1 is a crucial component of the process by which t-
PA binds to LRP-1 to exert its effects (165). HSCs express PAI-1, and more so when activated 
(Figure 19). Our preliminary studies show that when t-PA is added to primary HSC cultures, it is 
able to interact and cleave the endogenous PAI-1, suggesting there is complexing occurring in 
the culture medium (Figure 19). We have yet to determine whether our effects are at all 
dependent on t-PA:PAI-1 complexing, and whether the two-chain form of t-PA may have 
differential effects than single-chain t-PA in relation to binding ability to LRP1.  
Lastly, it is known that LRP1 can act as a moderator of TGF-β signaling; loss of LRP1 
from vascular smooth muscle cells results in constitutive TGF-β1 downstream signaling (96). 
When we treat cells with t-PA in combination with TGF-β1, t-PA is able to oppose the function 
of TGF-β1 (Figure 19), in contrast to kidney fibroblasts (Figure 8C). It remains to be studied in 
our system whether activation of TGF-β1 downstream signaling molecules, the SMADs, are 
disrupted after t-PA addition in combination with TGF-β1. If so, this would be one potential 
mechanism for action of t-PA in HSCs. 
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Figure 19. Effects of proteolytically-active t-PA in antagonism to TGF-β1. Primary HSCs were 
treated with two-chain t-PA for 24 hours in serum free conditions, alone or in combination with TGF-β1. 
Whole cell lysates (α-SMA and α-tubulin) or concentrated medium (PAI-1) were analyzed by western 
blotting. Boxed lanes highlight the ability of t-PA to counter the effect of TGF-β1 in primary HSCs. 
 
4.2.2 t-PA and LRP1 kinetics and distribution after injury 
Another critical question remaining is the exact contribution of different cell types to secreting t-
PA during injury and whether dysregulation of t-PA expression is a contributing factor to fibrosis 
progression. Despite undetectable levels of t-PA expression at baseline in liver (195), expression 
is increased in cirrhosis (196), and enzymatic activity is also increased by two days after acute 
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injury (116) in animal models. However, it is not clear which cells are producing t-PA in these 
scenarios, as only whole liver mRNA or homogenates were examined. Based on the data 
presented here, the local production and distribution of t-PA may affect rates of injury resolution. 
In our mouse liver injury model, we preliminarily looked for t-PA immunoreactivity at 
several time points after CCl4 injury, observing increased t-PA expression at day four and 
beyond, especially in the perivascular regions. In serial sections of the same tissue, we can 
identify some α-SMA+ cells in close proximity to t-PA localization, presumably vascular smooth 
muscle cells in periportal regions, and a mix of smooth muscle cells and activated HSCs around 
central vein regions (Figure 20). These data complement our Qdot studies at day four after injury 
(Figure 11C), where we show co-localized t-PA and α-SMA signal. Therefore, t-PA is increased 
in expression at relevant time points and locations to act upon MFB-like cells through LRP1.  
 
Figure 20. Immunohistochemical evaluation of t-PA expression during injury resolution in wildtype 
mice. Wildtype mice were given 0.05% phenobarbital (PB) for one week and then intraperitoneally injected 
twice with CCL4 (1 μL/g body weight) at days 7 and 10 post-PB induction. Livers were harvested at various 
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days after the last dose, embedded in paraffin, and serial sections were immunostained with anti-α-SMA or 
anti-t-PA antibody. Scale bars indicate 100μm. Black arrows indicate similar regions on serial sections. 
 
 
However, it remains unclear whether cells other than endothelial cells can produce t-PA 
after injury. It is possible that HSCs, or activated MFB-like cells, can be induced to produce t-PA 
and signal in a paracrine or autocrine fashion. To better understand the cellular sources of t-PA, 
we can use in situ hybridization for t-PA messenger RNA and double label tissue sections with 
antibodies against cell-specific markers. 
Another relevant question is whether the expression of LRP1 on HSCs is static or if it 
changes upon activation. Perhaps LRP1 is down-regulated upon MFB-like transition of HSCs, 
rendering them insensitive to LRP1 ligands and potentiating trans-differentiation. Double-
labeling with an HSC marker such as desmin and LRP1 and measuring relative expression 
between resting and injured livers would be one way to approach this question. Another way 
would be to isolate primary HSCs and grow them in culture over a period of about one week. 
HSCs plated on uncoated tissue-culture plates self-activate over time, so harvesting cells at 
different time points, from freshly plated to one week, and measuring the expression of LRP1 by 
western blot or immunostaining would be another approach. 
4.2.3 Evaluation of observed differences in t-PA null mice 
In Chapter 3, we discussed two incidental findings in t-PA null mice at day one after acute injury 
that have intriguing implications.  
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First was the observation of increased macrophage density in t-PA null mice after injury, 
which is of interest for two reasons. One is that in light of the other studies showing a role for t-
PA in macrophage recruitment (165, 191), it is paradoxical that we would have more, not less, 
macrophages at a site of injury. To address this issue, we need to first establish what the baseline 
macrophage populations are in the t-PA null mice in comparison to wildtype. If there is no 
difference at baseline, it is possible that the macrophage regression is what is impaired in this 
model and therefore more macrophages are sequestered in the liver after injury. If there is a 
baseline difference, then perhaps normal macrophage circulation is also impaired in t-PA null 
mice in addition to migration in response to injury as the other studies report. The second reason 
why these results are interesting is that macrophage activation and cytokine production promotes 
HSC activation after hepatic injury, so this may contribute to the sustained MFB-like population 
in the t-PA null mice starting from day five after injury. It would be of interest to stain tissues 
over the whole recovery study for F4/80 to track the entire course of macrophage flux after 
injury in our model. Also it would be enlightening to measure macrophage-specific cytokine 
production in t-PA null mice to see if there are elevations in cytokine levels or changes in 
macrophage polarity. 
The second observation we discussed in Chapter 3 was the differential regulation of 
CYP2E1 after liver injury in vivo. Since hepatocytes are the main cells that express the CYP 
enzymes, the changes noted in the t-PA null mice must be due to changes in the hepatocytes 
themselves in the setting of t-PA absence. A sustained expression in CYP2E1 in t-PA null mice 
renders them more sensitive to subsequent intoxication, while the wildtype hepatocytes have shut 
down expression to protect themselves from further injury. A first step in examining direct 
regulation of CYP2E1 by t-PA would be to add exogenous t-PA to pure primary hepatocyte 
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cultures and measure any changes in CYP2E1 expression over several time points. Additionally, 
although we have measured protein expression of CYP2E1 in the various groups, it is 
worthwhile to confirm that the differences we see at the protein level are matched by enzymatic 
activity. If t-PA could indeed regulate CYP enzyme expression in hepatocytes, this would define 
the first known direct phenotypic effect of t-PA on hepatocytes. 
4.2.4 Follow-up studies in LRP1 conditional null mice 
In Figure 13, we show that LRP1 conditional knockout mice also display increased numbers of 
MFB-like cells, using α-SMA as a marker, during recovery after injury. There are a few caveats 
to this study. First, the promoter for the Cre recombinase, SM22, is also a marker expressed in 
smooth muscle cells, rendering it not a perfect cell-specific marker in liver. This opens up the 
possibility that the effects that we see are partially due to contribution of vascular smooth muscle 
cell LRP1 loss. To confirm that effects we saw are indeed HSC-specific, we could follow up our 
studies with conditional LRP1 knockouts using a different Cre recombinase transgenic mouse, 
such as GFAP-cre. Although this marker is also not HSC-specific, the other cell types potentially 
affected are in the brain and therefore would not be confounding in analyzing hepatic MFB-like 
cell effects. Another caveat is that due to limited access to the mice, at the present we have not 
been able to establish a baseline for HSC numbers or phenotype for these mice. It could be 
possible that loss of LRP1 alone is sufficient to produce increase numbers of activated HSCs in 
the resting liver. 
These caveats aside, the next step in this line of investigation would be to follow up with 
the SM22-Cre LRP1 conditional knockout mice and test if they have aggravated fibrosis in a 
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chronic liver injury model such as what we have described in Chapter 3. This would be the 
ultimate test of whether LRP1 on HSCs ultimately plays a role in suppressing fibrogenesis. 
4.2.5 Evaluation the efficacy of t-PA treatment in chronic liver injury 
Finally, it has not escaped our notice that since t-PA is an FDA-approved drug, pursuit of using 
t-PA as a therapeutic in chronic liver disease has distinct advantages. However, many questions 
and proofs of concept remain before we can reasonably be assured of its clinical usefulness. 
Foremost, our chronic injury studies in the t-PA null mice are incomplete. 
Immunostaining for collagen I was a clean and useful first analysis; however, to confirm the 
results, we should measure total collagen content in the tissue using the standard hydroxyproline 
assay. In addition, it would be useful to know how long the sustained matrix deposition persists 
in the t-PA null mice beyond the time point in which the wildtypes completely resolve the injury 
and fibrosis. Time points of up to four weeks or more after the final injection may be useful for 
this purpose. In addition, evaluation of the mechanism for increased matrix deposition is needed. 
One possibility could be sustained MFB-like cell activation, in which case we should be able to 
detect increased numbers of α-SMA+ cells throughout the same time period as increased 
collagen deposition. But another possibility might be enhanced expression of collagen 
crosslinking enzymes such as lysyl oxidase, promoting mature fibrils that are hard to 
proteolytically digest, or impaired collagenase function secondary to loss of t-PA protease 
function. 
Finally, as we hypothesize that the primary mechanism that t-PA suppresses fibrosis is 
through LRP1-mediated signaling on HSCs, we predict that exogenous t-PA administration as a 
treatment concurrent to a chronic injury protocol would result in amelioration of fibrosis. 
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Further, if we were to use a proteolytically-inactive t-PA, we predict we would achieve the same 
result. If these were the case, the proteolytically-inactive t-PA should be considered as a potential 
drug for any future liver disease applications since it would decrease risk for hemorrhage (a 
concern in patients with liver failure due to decreased ability of the liver to produce clotting 
factors). Multiple sites on t-PA participate in binding to LRP1, although a higher affinity exists 
for the finger/growth factor domain on the very N-terminus; therefore, although another 
attractive alternative to total t-PA, it is not likely to be as effective (5). However, it is worth 
exploring whether other LRP1 ligands may be able to confer the same effects. Efficient 
activation of the receptor is seen with the receptor binding domain fragment of α2-macroglobulin 
(188) and could be tested as a proof of principle that LRP1 activation is the necessary step for 
any in vivo results. Also, testing u-PA might be another proof-of-concept. Interestingly, both of 
these LRP1 ligands have co-receptors that are unique to them (e.g. u-PAR), which further attest 
to the possibility that there are ligand-specific effects through the same signaling receptor. 
A last consideration would be how to administer t-PA in an organ-specific manner so as 
to minimize adverse effects in the kidney or brain. For our mouse experiments, the current 
proposal is to administer the t-PA via intraperitoneal injection, which ought to be absorbed into 
the portal circulation first; however, this would not be a practical route for patients. One 
possibility on the horizon is the use of nanotechnology or enteric coatings to produce orally-
administered capsules for protein drugs. If at least some of the protein can be absorbed through 
the intestinal lining, the first organ target for the t-PA would be the liver. Since hepatic clearance 
of t-PA is very efficient, smaller doses would ensure that only low concentrations of t-PA would 
escape first-pass by the liver. In this way, then, perhaps t-PA may be safely administered to 
patients with liver cirrhosis as an anti-fibrotic therapy, regardless of eitiology. 
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APPENDIX A 
TABLE OF MICROARRAY RESULTS 
Table 1. Fold changes in selected genes in HSC-T6 cells after treatment with t-PA. 
Fold Change Gene Name 
39.34 nitric oxide synthase 
36.12 lipocalin 2 (Lcn2) 
20.73 SERUM AMYLOID A-3  
11.93 nitric oxide synthase gene 
11.63 secretory leukocyte protease inhibitor (Slpi) 
11.25 CC chemokine ST38 precursor 
9.79 gro 
9.51 plasminogen activator inhibitor 2 type A (Pai2a) 
8.05 Weakly similar to nerve growth factor 
6.44 small inducible cytokine subfamily, member 2 (Scyb2) 
6.19 Moderately similar to RNP RAT RIBONUCLEASE PANCREATIC PRECURSOR 
6.02 CINC-2 alpha 
5.79 Superoxide dismutase 2, mitochondrial 
5.52 CINC-2 alpha 
5.49 latent transforming growth factor beta binding protein 2 
5.39 Weakly similar to T22286 hypothetical protein F46B6.3 
5.27 RAT SMALL INDUCIBLE CYTOKINE A7 PRECURSOR 
5.23 CINC-2 alpha 
4.99 Hydroxysteroid dehydrogenase, 11 beta type 1 (Hsd11b1) 
4.36 2,3-oxidosqualene:lanosterol cyclase 
4.06 Moderately similar to RR46_HUMAN Exosome complex exonuclease RRP46 
4.04 CXC chemokine LIX (LOC60665) 
3.99 Weakly similar to TRANSFORMING PROTEIN RHOB 
3.90 Colony stimulating factor 3 (granulocyte) (Csf3) 
3.77 Ceruloplasmin (ferroxidase) (Cp) 
3.72 Moderately similar to TRMU_HUMAN PROBABLE TRNA 
3.67 ATP-binding cassette, sub-family G (WHITE) 
3.47 CCAATenhancerbinding, protein (CEBP) delta 
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3.40 reg I binding protein I (Rbp1) 
3.23 Superoxide dismutase 2, mitochondrial  
3.18 Weakly similar to A45445 janusin precursor, long form - rat  
3.17 Highly similar to JE0174 frizzled protein-2  
3.16 Fatty acid binding protein 3, muscle and heart (Fabp3) 
3.07 IKBA_RAT NF-kappaB inhibitor alpha  
2.89 Moderately similar to S04363 class II histocompatibility antigen RT1-B alpha 
2.87 Interleukin 6 (interferon, beta 2) (Il6) 
2.86 Complement component 3 (C3) 
2.84 Retinol-binding protein 1 (Rbp1) 
2.82 Highly similar to A56640 CDC4 repeat unit-containing protein - mouse 
2.78 Weakly similar to FCN2_RAT Ficolin 2 precursor 
2.77 retinoid X receptor gamma 
2.75 GPI-anchored ceruloplasmin 
2.71 cyclooxygenase 2  
2.68 syntaxin 1 a 
2.68 Weakly similar to LIPB_YEAST PROBABLE LIPOATE-PROTEIN LIGASE B, 
MITOCHONDRIAL  
2.65 DEAD (aspartate-glutamate-alanine-aspartate) box polypeptide 25 (Ddx25) 
2.63 Highly similar to URIDINE PHOSPHORYLASE 
2.63 Mitogen-activated protein kinase kinase kinase 8 (Map3k8) 
2.61 Potassium (K+) channel protein alpha 5  
2.54 oxidised low density lipoprotein (lectin-like) receptor 1 (Olr1) 
2.52 hemopexin (Hpx) 
2.36 Acid nuclear phosphoprotein 32 (leucine rich) (Anp32) 
2.33 Weakly similar to CLD3 RAT CLAUDIN-3 
2.32 Weakly similar to C42D8.3.p (Caenorhabditis elegans) 
2.32 solute carrier family 19 (sodiumhydrogen exchanger), member 1 (Slc19a1) 
2.32 versican Vint isoform 
2.25 Highly similar to COMPLEMENT C2 PRECURSOR  
2.23 Weakly similar to RNA polymerase I (127 kDa subunit) 
2.20 GPI-anchored ceruloplasmin 
2.20 homeobox protein (R1b) 
2.19 Moderately similar to JC6307 homeobox protein Barx2 - mouse  
2.18 Weakly similar to T20358 hypothetical protein D2030.8  
2.15 Moderately similar to U2R2 MOUSE U2 SMALL NUCLEAR RIBONUCLEOPROTEIN 
AUXILIARY FACTOR 35 KD 
2.15 Highly similar to VTL1_MOUSE Vesicle transport v-SNARE protein Vti1-like 1  
2.13 Weakly similar to KRP1_RAT Kelch-related protein 1 
2.10 translocator of inner mitochondrial membrane 44 (Timm44) 
2.09 CCAATenhancerbinding, protein (CEBP) delta (Cebpd) 
2.06 Stromal cell-derived factor 1 
2.04 Small inducible gene JE (Scya2) 
2.04 Hydroxysteroid dehydrogenase, 11 beta type 2 (Hsd11b2) 
2.01 small inducible cytokine subfamily D, 1 (Scyd1) 
   
-1.47 alpha-SMA 
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-2.00 Adrenergic, alpha 1B-, receptor (Adra1b) 
-2.00 Moderately similar to KIAA0351 
-2.00 endo-alpha-mannosidase (Enman) 
-2.01 Weakly similar to APP2 RAT AMYLOID-LIKE PROTEIN 2 PRECURSOR 
-2.01 elongation factor-2 kinase  
-2.01 Highly similar to T08771 hypothetical protein DKFZp586L151.1 
-2.03 small rec (srec)  
-2.03 Weakly similar to JE0343 terf protein - rat 
-2.03 serotonin 5-HT2C receptor 
-2.03 trefoil factor 1 (Tff1) 
-2.04 Annexin A3 
-2.04 regulator of G-protein signaling 14 (Rgs14) 
-2.05 Gap junction protein, alpha 1, 43 kD (connexin 43) 
-2.05 retinol dehydrogenase homolog (Rdhl) 
-2.05 Highly similar to A4 RAT ALZHEIMERS DISEASE AMYLOID A4 PROTEIN HOMOLOG 
PRECURSOR 
-2.05 Moderately similar to S04363 class II histocompatibility antigen RT1-B alpha 
-2.05 Highly similar to casein kinase 1 gamma 3 isoform 
-2.05 Highly similar to T47180 hypothetical protein DKFZp434C2316.1 
-2.05 Insulin-like growth factor-binding protein 5 
-2.06 amphiregulin (Areg) 
-2.06 Tyrosine hydroxylase (Th) 
-2.06 Weakly similar to apolipoprotein L, 3; TNF-inducible protein CG12-1 
-2.06 Moderately similar to HUD RAT PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGEN HUD 
-2.06 gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 6 (Gabra6) 
-2.07 plasma membrane Ca2+-ATPase isoform 4  
-2.07 Weakly similar to T23273 hypothetical protein Y63D3A.8  
-2.07 synaptopodin (Synpo) 
-2.07 exostoses (multiple)-like 3 (Extl3) 
-2.07 calpain 10 (Capn10) 
-2.09 norvegicus guanosine monophosphate reductase (Gmpr) 
-2.09 AGAL MOUSE ALPHA-GALACTOSIDASE A PRECURSOR 
-2.10 transforming growth factor, beta receptor III (Tgfbr3) 
-2.10 solute carrier family 21 (organic anion transporter), member 9 (Slc21a9) 
-2.11 Weakly similar to S25644 Ig mu chain C region - rat 
-2.11 Drosophila discs-large tumor suppressor homologue (synapse associated protein) (Dlg1) 
-2.11 Moderately similar to MTM1_MOUSE MYOTUBULARIN 
-2.11 strain BNCrl glucocorticoid receptor 
-2.11 Highly similar to SC14_HUMAN SEC14-LIKE PROTEIN 
-2.11 Weakly similar to F56A11.5.p 
-2.11 bone morphogenetic protein 2 (Bmp2) 
-2.12 Weakly similar to JG0164 LIM protein, FHL4 
-2.12 Highly similar to GLUTATHIONE S-TRANSFERASE 8  
-2.13 Gap junction membrane channel, protein alpha 4 (connexin 37) (Gja4) 
-2.13 Weakly similar to T16005 hypothetical protein F09E5.2 - 
-2.13 Weakly similar to CALM_HUMAN CALMODULIN 
-2.14 low density lipoprotein receptor-related protein 3 (Lrp3) 
-2.14 solute carrier family 31 (copper transporters), member 1 (Slc31a1) 
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-2.14 Regeneration protein, lithostatin, pancreatic stone protein (Reg1) 
-2.15 Tissue inhibitor of metalloproteinase 3 
-2.15 Weakly similar to A Chain A, Crystal Structure Of S-Glutathiolated Carbonic Anhydrase Iii 
-2.16 Weakly similar to FMOD RAT FIBROMODULIN PRECURSOR 
-2.16 NaPi-2 gamma 
-2.17 Glutathione-S-transferase, alpha type (Yc?) (Gsta2) 
-2.19 Weakly similar to polypeptide GalNAc transferase T1 (Rattus norvegicus)  
-2.23 Solute carrier family 2 A3 (neuron glucose transporter) (Slc2a3) 
-2.23 Moderately similar to Y084_HUMAN HYPOTHETICAL PROTEIN KIAA0084 
-2.24 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide (Adh7) 
-2.26 N-myc downstream-regulated gene 2 (Ndrg2) 
-2.27 Highly similar to S58008 GPI-anchored protein 
-2.27 Weakly similar to development-related protein 
-2.29 solute carrier family 12, (potassium-chloride transporter) member 5 (Slc12a5) 
-2.30 Glial cell line-derived neurotrophic factor receptor alpha (Gfra1) 
-2.31 prostaglandin D2 synthase 2, hematopoietic (Ptgds2) 
-2.32 Highly similar to D4DR RAT D(4) DOPAMINE RECEPTOR 
-2.32 putative pheromone receptor (Go-VN1) 
-2.33 Weakly similar to MATERNAL PUMILIO PROTEIN 
-2.34 Highly similar to LHX1 MOUSE LIMHOMEOBOX PROTEIN LHX1 
-2.34 proto-oncogene (Met) 
-2.36 Weakly similar to T46436 hypothetical protein DKFZp434I1926.1 
-2.39 hairy and enhancer of split 5 
-2.43 Moderately similar to LEF1 RAT LYMPHOID ENHANCER BINDING FACTOR 1  
-2.44 proliferin-related protein (Plfr) 
-2.46 Weakly similar to FMOD RAT FIBROMODULIN PRECURSOR 
-2.48 Mg1  
-2.49 Highly similar to A4 RAT ALZHEIMERS DISEASE AMYLOID A4 PROTEIN HOMOLOG 
PRECURSOR 
-2.54 Weakly similar to A40805 b-locus protein - mouse 
-2.55 Highly similar to 2008147B protein RAKc 
-2.56 cholinergic receptor, nicotinic, alpha polypeptide 6 (Chrna6) 
-2.58 myocilin (Myoc) 
-2.59 GABA transporter (RNU28927) 
-2.59 collagen XII alpha 1 (Col12a1) 
-2.62 Highly similar to I60125 PDGF receptor beta-like tumor suppressor (H.sapiens) 
-2.62 wingless-type MMTV integration site family, member 4 (Wnt4) 
-2.63 Weakly similar to GSHC RAT GLUTATHIONE PEROXIDASE 
-2.64 Weakly similar to ZN42_HUMAN ZINC FINGER PROTEIN 42  
-2.65 ERM-binding phosphoprotein  
-2.68 Weakly similar to similar to C.elegans hypothetical protein CET01H8.1,CEC05C12.3,CEF54D1.5. 
similar to trp and trp-like proteins  
-2.69 130kDa-Ins(1,4,5)P3 binding protein (LOC84587) 
-2.72 angiopoietin-like 2 (Angptl2) 
-2.86 Highly similar to A47220 dermatopontin precursor 
-2.87 Weakly similar to S26689 hypothetical protein hc1 - mouse 
-2.89 CA3 mRNA for carbonic anhydrase III 
-2.98 Alcohol dehydrogenase (class I), alpha polypeptide (Adh1a) 
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-3.00 Weakly similar to T00636 hypothetical protein F21856_2 
-3.00 Vasopressin receptor V1a (Avpr1a) 
-3.01 resistin like alpha (Retnla) 
-3.03 dihydrodiol dehydrogenase 
-3.05 growth hormone secretagogue receptor type 1a 
-3.22 salivary protein 1 (Spt1) 
-3.30 Weakly similar to T08802 hypothetical protein DKFZp586D0623.1 (H.sapiens) 
-3.33 aldehyde oxidase (Aox1) 
-3.43 Serotonin (5-hydroxytryptamine (5HT)) receptor, type 1B (Htr1b) 
-3.60 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A (Sema3a) 
-3.70 Moderately similar to Y188_HUMAN HYPOTHETICAL PROTEIN KIAA0188  
-3.70 GDNF receptor alpha  
-3.88 WNT1 inducible signaling pathway protein 2 (Wisp2) 
-4.24 prostaglandin E receptor EP2 subtype  
-4.34 Alkaline phosphatase 1, intestinal, defined by SSR (Alpi) 
-4.52 transmembrane 4 superfamily member 3 (Tm4sf3) 
-5.24 myosin Ic (Myo1c) 
-6.97 Weakly similar to F43B10.2.p (Caenorhabditis elegans)  
-8.31 Highly similar to TCPZ MOUSE T-COMPLEX PROTEIN 1, ZETA SUBUNIT 
-10.63  Cu++ transporting, alpha polypeptide (Menkes syndrome) (Atp7a) 
-11.03 damage-specific DNA binding protein 1 (DDB1 gene) 
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Table 2. Absolute changes in selected genes in HSC-T6 cells after treatment with t-PA. 
Relative copy 
number difference 
(t-PA - Vehicle)  
Gene Name 
-3884.8 osteopontin 
-3062.4 Col3a1 
-2472.9 Col1a2  
-2460.3 Diaphorase (NADHNADPH) /DEF=Rat NAD(P)H:menadione oxidoreductase 
-2459.9 Id3a 
-2057.6 RUK-l (Ruk) 
-2027.8 collagen type V, alpha 2 
-1826.6 catalase 
-1795.6 SH3 domain-containing adapter protein isoform SETA-1x23 (SETA) 
-1775.4 stearoyl-CoA desaturase 2  
-1753.9 Weakly similar to POL3 MOUSE RETROVIRUS-RELATED POL POLYPROTEIN 
-1639.3 osteonectin 
-1518.2 villin 2 
-1503.4 Highly similar to T4S1_MOUSE Transmembrane 4 superfamily, member 1 (Tumor-
associated antigen L6) 
-1437.1 stearoyl-Coenzyme A desaturase 2 (Scd2) 
-1415 Nogo-C protein 
-1361.8 Weakly similar to POL3 MOUSE RETROVIRUS-RELATED POL POLYPROTEIN 
-1329.9 Signal transducer and activator of transcription 1 (Stat1) 
-1321.5 PKC-delta binding protein (SRBC) 
-1308.4 Rap7a 
-1235.3 aldose reductase-like protein 
-1218.5 Transforming growth factor beta stimulated clone 22 (Tgfb1i4) 
-1218.3 selectin, endothelial cell, ligand (Selel) 
-1191.3 Highly similar to ITMB MOUSE INTEGRAL MEMBRANE PROTEIN 2B 
(M.musculus) 
-1191.2 Moderately similar to RB48 MOUSE CHROMATIN ASSEMBLY FACTOR 1 P48 
SUBUNIT  
-1147.8 homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain 
member 1 (Herpud1) 
-1129.2 Weakly similar to NOMR RAT NEURONAL OLFACTOMEDIN-RELATED ER 
LOCALIZED PROTEIN PRECURSOR 
-1123 BM1av1 MHC class Ib antigen, strain DA 
-1079.2 Annexin 1 (p35) (Lipocortin 1) (Anxa1) 
-1075.1 Insulin-like growth factor binding protein 6 (Igfbp6) 
-1059.6 Secreted acidic cystein-rich glycoprotein (osteonectin) (Sparc) 
-1045 Ryudocansyndecan 2  
-1036.7 Highly similar to SRE1_RAT Sterol regulatory element binding protein-1  
-1032.4 collagen alpha1 type I 
-1028.4 Moderately similar to C560_HUMAN SUCCINATE DEHYDROGENASE 
CYTOCHROME B560 SUBUNIT, MITOCHONDRIAL PRECURSOR 
-1014.7 Prion protein, structural 
-970.6 upregulated by 1,25-dihydroxyvitamin D-3  
-966.7 tissue inhibitor of metalloproteinase 2 (Timp2) 
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-965.5 membrane-type matrix metalloproteinase 
-942.8 Highly similar to S70642 ubiquitin ligase Nedd4 - rat 
-936.9 disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) (Dab2) 
-929 Highly similar to CDC28 protein kinase 1; cyclin-dependent kinase regulatory subunit 1 
(Mus musculus) 
-924 Peripherin (Prph) 
-921.5 brain expressed X-linked 3 (Bex3) 
-916 heterogeneous nuclear ribonucleoprotein K 
-905.6 transmembrane 4 superfamily member 3 (Tm4sf3) 
-905.5 Guanine nucleotide-binding protein beta 1 
-897 S61A RAT PROTEIN TRANSPORT PROTEIN SEC61 ALPHA SUBUNIT  
-894.4 coated vesicle membrane protein (Rnp24) 
-881.5 Early growth response 1 (Egr1) 
-874.8 Peripheral myelin protein 
-868.2 GLUT4 vesicle 20kDa protein 
-860.2 S-100 related protein, clone 42C (S100A10) 
-858.7 Crystallin, alpha polypeptide 2 (Cryab) 
-846 Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 
-838.9 Highly similar to I84741 RNA helicase - mouse (M.musculus) 
-835.2 CD151 antigen (Cd151) 
-835 follistatin-related protein precursor 
-833.4 follistatin-related protein precursor (Frp) 
-831.4 Isocitrate dehydrogenase 1, soluble (Idh1) 
-825.6 inhibitor of DNA binding  
-822 Insulin-like growth factor 2 receptor 
-813.4 Moderately similar to delta-6 fatty acid desaturase  
-806.2 Highly similar to Y193_HUMAN HYPOTHETICAL PROTEIN KIAA0193 
-803.7 Highly similar to T14738 hypothetical protein DKFZp564A2416.1  
-797.1 Tropomyosin 4 (Tpm4) 
-795.9 peptidyl-glycine alpha-amidating monooxygenase (rPAM-2) mRNA 
-794.7 collagen, type V, alpha 1 (Col5a1) 
-789.6 Highly similar to GELS MOUSE GELSOLIN  
-788.5 fatty acid desaturase 1 (Fads1) 
-786.6 lamin A 
-784.3 xanthine dehydrogenase (Xdh) 
-783.6 Weakly similar to T46436 hypothetical protein DKFZp434I1926.1  
-771.5 Ryudocansyndecan 2 
-768.8 Highly similar to T46500 hypothetical protein DKFZp434D098.1 (H.sapiens) 
-764.3 transmembrane receptor Unc5H2 (Unc5h2) 
-761.8 sodiumpotassium ATPase alpha-1 subunit truncated isoform 
-761 Moderately similar to S71356 glucocorticoid-attenuated response gene 49 protein 
-760.6 procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos 
syndrome type VI) (Plod) 
-759.7 S100 calcium-binding protein A4 (S100a4) 
-753.1 Moderately similar to T17320 hypothetical protein DKFZp564J0863.1 (H.sapien 
-753 Heme oxygenase (Hmox1) 
-751.2 dithiolethione-inducible gene-1 (DIG-1) 
-750.1 Weakly similar to TYROSINE-PROTEIN KINASE JAK2  
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-750 endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 2 (Edg2) 
-749.5 Weakly similar to T22416 hypothetical protein F49C12.12 - Caenorhabditis elegans 
(C.elegans) 
-749.5 prolyl 4-hydroxylase alpha subunit 
-732.1 Weakly similar to cyclophilin B 
-728.2 Highly similar to S66254 dolichyl-diphosphooligosaccharide--protein glycotransferase 
(H.sapiens) 
-715 Highly similar to IBP6 RAT INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 
6 PRECURSOR  
-709.6 PDZ and LIM domain 1 (elfin) (Pdlim1) 
-707.3 cysteine-rich protein 2 (Csrp2) 
-696.7 Weakly similar to SP10_MOUSE NUCLEAR AUTOANTIGEN SP-100 
-696.7 Weakly similar to putative serinethreonine protein kinase MAK-V 
-693.5 Highly similar to A4 RAT ALZHEIMERS DISEASE AMYLOID A4 PROTEIN 
HOMOLOG PRECURSOR 
-690 Signal transducer and activator of transcription 1 
-689.9 Highly similar to GLUTATHIONE S-TRANSFERASE 8 
-681.5 Weakly similar to R155.1.p (Caenorhabditis elegans) 
-680.9 Glutathione-S-transferase, alpha type (Ya) (Gsta1) 
-672.3 Microtubule-associated protein 2 
-670.7 BM1k MHC class Ib antigen 
-670.1 Transforming growth factor, beta 3 (Tgfb3) 
-662.5 Highly similar to T00056 hypothetical protein KIAA0418 
-660.6 CBP-50 protein 
-658.4 Highly similar to ER23_HUMAN ER LUMEN PROTEIN RETAINING RECEPTOR 3  
-648.6 Weakly similar to FMOD RAT FIBROMODULIN PRECURSOR 
-634.8 Highly similar to MTRP MOUSE GOLGI 4-TRANSMEMBRANE SPANNING 
TRANSPORTER  
-628.9 TIMP2 
-627.4 Moderately similar to F22B5.10.p (Caenorhabditis elegans) 
-626.8 Moderately similar to S04363 class II histocompatibility antigen RT1-B alpha 
-623.8 annexin VI 
-622.6 Moderately similar to T43496 hypothetical protein DKFZp434J039.1  
-616.5 cyclase-associated protein homologue 
-614.4 plasma glutamate carboxypeptidase (Pgcp-pending) 
-612.3 moesin (Msn) 
-612.1 ARP2_HUMAN ACTIN-LIKE PROTEIN 2  
-609.8 unction plakoglobin (Jup) 
-609.4 Weakly similar to F55A12.9a.p (Caenorhabditis elegans)  
-604.9 Moderately similar to COG2_MOUSE Coatomer gamma-2 subunit (Gamma-2 coat 
protein) 
-603.9 Moderately similar to FINC RAT FIBRONECTIN PRECURSOR 
-603.8 Weakly similar to RETROVIRUS-RELATED POL POLYPROTEIN 
-603.6 CD14 antigen 
-600.8 HIF-1 responsive RTP801 (Rtp801) 
-597.1 Highly similar to JE0223 destrin - rat  
-593.2 CaBP1 
-592.3 alanyl (membrane) aminopeptidase (Anpep) 
-587.3 Highly similar to CA1B RAT COLLAGEN ALPHA 1(XI) CHAIN 
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-584 Fucosidase, alpha-L-1, tissue (Fuca1) 
  
667.9 calmodulin 
670.1 tropomyosin non-muscle isoform NM1 (TPM-gamma) 
670.8 Highly similar to Sin3-associated polypeptide 18 
672 Highly similar to C8  
672.8 Weakly similar to T32886 hypothetical protein C34B2.8  
675.9 cyclin-dependent kinase inhibitor 2a p16Ink4a (Cdkn2a) 
676.5 Moderately similar to SKD1 MOUSE SKD1 PROTEIN 
677 Weakly similar to T-COMPLEX PROTEIN 1, ALPHA SUBUNIT 
677.8 C-terminal binding protein 1 (Ctbp1) 
678.8 Highly similar to HETEROCHROMATIN PROTEIN 1 HOMOLOG GAMMA 
681.6 Ceruloplasmin (ferroxidase) (Cp) 
684.1 Mx1 protein 
684.4 Moderately similar to T30249 cell proliferation antigen Ki-67  
685.6 ATP synthase subunit d (Atp5jd) 
688 Moderately similar to selective hybridizing clone 
689.5 H3 histone, family 3B  
689.9 matrin 3 (Matr3) 
690.4 immunophilin FKBP12 
690.6 Weakly similar to MIC2_HUMAN T-CELL SURFACE GLYCOPROTEIN E2 
PRECURSOR  
690.9 Weakly similar to T-COMPLEX PROTEIN 1, ALPHA SUBUNIT 
693.8 parathymosin (Ptms) 
696.3 Weakly similar to SFR2_MOUSE Splicing factor, arginineserine-rich 2 
698.6 Highly similar to adaptor-related protein complex AP-3, delta subunit 
700.1 G protein gamma-5 subunit 
700.3 transcription factor A, mitochondrial (Tfam) 
701.3 Phosphoglycerate mutase 1 (Pgam1) 
703.4 Atp5c1  
703.8 Moderately similar to T14773 hypothetical protein DKFZp564B0482.1  
704.3 Highly similar to U123_HUMAN HYPOTHETICAL 12.4 KDA PROTEIN BK223H9.2  
705.2 versican V3 isoform precursor 
705.9 casein kinase II beta subunit 
709.3 Moderately similar to splicing factor, arginineserine-rich 6 
709.9 Weakly similar to PRSC MOUSE 26S PROTEASOME REGULATORY SUBUNIT S12 
710.3 NonOp54nrb homolog mRNA 
711.4 Cell division cycle control protein 2 
711.6 Moderately similar to pumilio; pumuckel; ovarette; bemused  
712.8 aldo-keto reductase family 1, member A1 
713.2 interacting protein 30 (Sip30) 
713.8 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9) isoform 
3 (Atp5g3) 
715.3 Highly similar to S22655 translation elongation factor eEF-1 gamma chain 
715.7 Highly similar to PFD2_MOUSE PREFOLDIN SUBUNIT 2  
716.1 nucleolar phosphoprotein of 140kD, Nopp140  
720.1 tissue factor pathway inhibitor (Tfpi) 
720.3 Weakly similar to GBB1 RAT GUANINE NUCLEOTIDE-BINDING PROTEIN 
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G(I)G(S)G(T) BETA SUBUNIT 1 
721.9 cyclooxygenase 2  
722.8 norvegicus eukaryotic translation initiation factor 4E binding protein 1 (Eif4ebp1) 
725.2 Highly similar to PLS1 MOUSE PROLIFERATION-ASSOCIATED PROTEIN 1 
726.3 solute carrier family 7 member A1 (amino acidtransporter cationic 1)  
726.6 Highly similar to budding uninhibited by benzimidazoles 3 homolog (S. cerevisiae) 
727.2 transcription elongation factor B (SIII) polypeptide 2 
731.7 zinc finger protein Y1  
734.9 nuclear RNA helicase, DECD variant of DEAD box family (Ddxl) 
735.8 DNA primase small subunit  
736.1 Cytochrome C 
738.7 tumor-associated protein 1 
740.3 phosphatidylethanolamine binding protein (Pbp) 
740.5 HG17 RAT NONHISTONE CHROMOSOMAL PROTEIN HMG-17  
742.2 ferritin light chain subunit  
743.7 NTF2 gene 
745.2 Highly similar to PROTEASOME SUBUNIT RC6-1 
746.7 Weakly similar to S26689 hypothetical protein hc1 - mouse 
748.6 fertility protein SP22 
749.3 Weakly similar to S11349 nonhistone chromosomal protein HMG-17 - rat 
750.2 small zinc finger-like protein (TIM13) 
752.6 Moderately similar to DHSD_HUMAN SUCCINATE DEHYDROGENASE 
754.1 nitric oxide synthase gene 
754.9 Highly similar to RPCX MOUSE DNA-DIRECTED RNA POLYMERASES I, II, AND 
III 7.0 KD POLYPEPTIDE 
755.2 Highly similar to DIAMINE ACETYLTRANSFERASE 
756 Weakly similar to NFH MOUSE NEUROFILAMENT TRIPLET H PROTEIN 
756.4 Weakly similar to JC5521 TATA-binding protein-interacting protein 49 - rat 
757.1 Moderately similar to I Chain I, Beta-Galactosidase (Chains I-P) 
757.5  Nopp140 associated protein (Nap65) 
758.2 Weakly similar to SYW MOUSE TRYPTOPHANYL-TRNA SYNTHETASE 
764 Highly similar to CNIH MOUSE CORNICHON HOMOLOG 
764.2 solute carrier family 25 (mitochondrial adenine nucleotide translocator) member 4 
767.5 Moderately similar to UCRH_HUMAN UBIQUINOL-CYTOCHROME C 
REDUCTASE COMPLEX 11 KDA PROTEIN PRECURSOR  
767.8 integrin-linked kinase (Ilk) 
768.5 proteasome (prosome, macropain) subunit, beta type, 4 (Psmb4) 
768.6 orphan seven transmembrane receptor (Ieda) 
768.8 DDRT helix-destabilizing protein - rat 
771.2 Tumor protein p53 (Li-Fraumeni syndrome) (Tp53) 
772.2 Highly similar to S25111 alpha-2-macroglobulin receptor precursor - mouse 
776.1 Weakly similar to S46930 teg292 protein - mouse  
777.4 glycine cleavage system protein H (aminomethyl carrier) (Gcsh) 
777.9 Weakly similar to T15543 hypothetical protein C18A3.3 
778.6 Prosaposin (sulfated glycoprotein, sphingolipid hydrolase activator) (Psap) 
778.9 cytoplasmic beta-actin (Actx) 
781 Weakly similar to T27859 hypothetical protein ZK430.5 
781.7 Highly similar to AF151857 1 CGI-99 protein 
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782.1 tyrosine 3-monooxygenasetryptophan 5-monooxygenase activatioprotein 
787.2 proteasome (prosome, macropain) subunit, beta type, 2 (Psmb2) 
787.8 Highly similar to IF37 MOUSE EUKARYOTIC TRANSLATION INITIATION 
FACTOR 3 SUBUNIT 7 
788.3 Highly similar to translation initiation factor eIF3 p40 subunit (H.sapiens) 
792 outer mitochondrial membrane receptor rTOM20  
796.1 Protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform (Ppp2cb) 
803.1 Protein phosphatase 1, catalytic subunit, gamma isoform 1 (Ppp1cc) 
804.4 Highly similar to B Chain B, Crystal Structure Of The D1d2 Sub-Complex From The 
Human Snrnp Core Domain 
805.4 Moderately similar to ribosomal protein L33-like protein 
808 ribosomal protein L30 
808.1 large subunit ribosomal protein L36a (Rpl36a) 
809.2 Weakly similar to intracellular chloride ion channel protein p64H1  
811.2 eukaryotic initiation factor 5 (eIF-5) 
811.5 bone marrow stromal cell antigen 1  
812.4 cytoplasmic beta-actin 
815.3 solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 
(Slc3a2) 
816.3 myosin regulatory light chain (RLC) 
817.6 Highly similar to LSM4_MOUSE U6 SNRNA-ASSOCIATED SM-LIKE PROTEIN 
LSM4 
818.7 ubiquitin A-52 residue ribosomal protein fusion product 1 (Uba52) 
818.9 splicing factor 3b, subunit 3, 130kD; spliceosome-associated protein 130 (Homo sapiens) 
819.9 Moderately similar to COXM MOUSE CYTOCHROME C OXIDASE POLYPEPTIDE 
VIIB PRECURSOR 
824.6 Highly similar to H33_HUMAN HISTONE H3.3 
827.1 Highly similar to HSPC014  
828.4 heterogeneous nuclear ribonucleoprotein A1 
829.2 Highly similar to 60S RIBOSOMAL PROTEIN L8  
832.6 Highly similar to PRCE RAT PROTEASOME EPSILON CHAIN PRECURSOR 
833.8 Bax protein splice variant k 
834.7 Highly similar to MGN_HUMAN MAGO NASHI PROTEIN HOMOLOG 
835.5 proteasome (prosome, macropain) subunit, beta type 1 (Psmb1) 
837.4 Farnesyl diphosphate synthase (Fdps) 
837.9 Highly similar to T46901 hypothetical protein DKFZp761C10121.1  
839 Calmodulin 1 (phosphorylase kinase, delta) 
841.4 heterogeneous nuclear ribonucleoprotein L 
843.9 voltage-dependent anion channel 1 (Vdac1) 
849 mitochondrial protonphosphate symporter  
850.4 fatty acid synthase 
853.2 small inducible cytokine subfamily, member 2 (Scyb2) 
854.4 syntenin (Sdcbp) 
858.8 Peptidylprolyl isomerase A (cyclophilin A)  
859.6  MHC class I RT1.E protein mRNA 
860.3 proteasome (prosome, macropain) subunit, alpha type 1 (Psma1) 
860.5  proteasome (prosome, macropain) subunit, beta type, 7 (Psmb7) 
862.1 Cytochrome C, expressed in somatic tissues (Cycs) 
866.2 Highly similar to translation intiation factor eIF-3 p110 subunit 
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867 Moderately similar to T13381 hypothetical protein EG:115C2.12 - fruit fly 
867.2 Proliferating cell nuclear antigen (Pcna) 
874.6 Weakly similar to PC1154 tumor rejection antigen P815 - mouse  
882.7 Siahbp1 
882.8 vesicle-associated membrane protein, associated protein A (33 kDa) 
883.6 Highly similar to TF19 MOUSE TFAR19 PROTEIN 
886.4 Weakly similar to Ribosomal protein L11  
887 Highly similar to I55595 splicing factor 
889.1 FK506-binding protein 1 (12kD) 
897.4 metallothionein 1 
899.3 LPS-induced TNF-alpha factor 
903.8 Pyruvate kinase 3 (Pkm2) 
903.8 GPI-anchored ceruloplasmin 
908.4 Highly similar to P2CG MOUSE PROTEIN PHOSPHATASE 2C GAMMA ISOFORM 
911.1 proteasome (prosome, macropain) subunit, alpha type 4 (Psma4) 
913.7 T-complex 1 
914.9 guanosine diphosphate (GDP) dissociation inhibitor 2 
933.6 Highly similar to IF6 MOUSE EUKARYOTIC TRANSLATION INITIATION FACTOR 
6 
933.8 Highly similar to ACTB_HUMAN ACTIN, CYTOPLASMIC 1  
936.5 Tyrosine 3-monooxygenasetryptophan 5-monooxygenase activation protein, theta 
938.9 Highly similar to TPM1 RAT TROPOMYOSIN, FIBROBLAST ISOFORM 1 
(R.norvegicus) 
940 Superoxide dismutase 1, soluble (Sod1) 
940.3 mitochondrial ATP synthase beta subunit 
942.3 putative ionotropic glutamate receptor GLURR-F11694B (Glurr) 
947.7 Highly similar to GTO1_RAT GLUTATHIONE TRANSFERASE OMEGA 1 (GSTO 1-
1) 
953.1 Histone H1-0 (H1f0) 
964.3 transporter protein; system N1 Na+ and H+-coupled glutamine transporter 
965 prothymosin alpha 
970.3 Highly similar to SFR2_MOUSE Splicing factor, arginineserine-rich 2 (Splicing factor 
SC35) (SC-35) 
980.6 Moderately similar to SYQ_HUMAN GLUTAMINYL-TRNA SYNTHETASE  
987 Highly similar to ring-box 1; ring-box protein 1  
989.6 Weakly similar to UCRQ_HUMAN UBIQUINOL-CYTOCHROME C REDUCTASE 
COMPLEX UBIQUINONE-BINDING PROTEIN QP-C  
991.3 proteasome (prosome, macropain) subunit, alpha type 3 (Psma3) 
997 Rat unidentified mRNA expressed in embryo and tumor but not normal differentiated  
1001 class I beta-tubulin 
1002.2 Weakly similar to S45359 polyubiquitin 10 - rat 
1004.7 Weakly similar to PAB1 MOUSE POLYADENYLATE-BINDING PROTEIN 1  
1015.6 microsomal glutathione S-transferase 1 (Mgst1) 
1018.7 Weakly similar to T22490 hypothetical protein Y37A1B.1 - Caenorhabditis eleg 
1025.3 Highly similar to EXT1 MOUSE EXOSTOSIN-1 (M.musculus) 
1030.2 CCAATenhancerbinding, protein (CEBP) delta 
1031.9 Moderately similar to UCR6_HUMAN UBIQUINOL-CYTOCHROME C REDUCTASE 
COMPLEX 14 KDA PROTEIN (H.sapiens) 
1034.2 ribosomal protein L27 
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1036.3 Weakly similar to HS9B RAT HEAT SHOCK PROTEIN HSP 90-BETA (R.norvegicus) 
1041.9 protease, serine, 11 (Igf binding) (Prss11) 
1044.7 protease (prosome, macropain) 28 subunit, alpha (Psme1) 
1046.5 Tegt 
1046.8 protein tyrosine phosphatase 4a1 
1049 Highly similar to IRF7 MOUSE INTERFERON REGULATORY FACTOR 7 
1049.4 H3 histone, family 3B  
1051 LY6E_MOUSE LYMPHOCYTE ANTIGEN LY-6E PRECURSOR (THYMIC 
SHARED ANTIGEN-1) (TSA-1) 
1051.6 tissue inhibitor of metalloproteinase 1 (Timp1), 
1053.1 Weakly similar to T-COMPLEX PROTEIN 1, ALPHA SUBUNIT (R.norvegicus) 
1059.4 hypoxia inducible factor 1, alpha subunit (Hif1a) 
1060.8 Highly similar to NAD-DEPENDENT METHYLENETETRAHYDROFOLATE 
DEHYDROGENASE METHENYLTETRAHYDROFOLATE CYCLOHYDROLASE 
MITOCHONDRIAL PRECURSOR  
1072.8 Weakly similar to ROD_RAT HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN D0 (HNRN 
1077.8 Highly similar to SYS_HUMAN SERYL-TRNA SYNTHETASE (H.sapiens) 
1078.9 Weakly similar to UBIQUITIN-CONJUGATING ENZYME E2-17 KD 2 (R.norvegicus) 
1084.9 cytochrome c oxidase subunit Va preprotein 
1087.7 macrophage migration inhibitory factor (Mif) 
1088.5 endolyn (Cd164) 
1090.8 CCAATenhancerbinding, protein (CEBP) delta (Cebpd) 
1102.7 MHC class I RT1 (RT21) 
1103 peroxiredoxin 3 (Prdx3) 
1103.1 Weakly similar to T34105 hypothetical protein C17G10.8 
1110.4  cytochrome c oxidase, subunit IVa (Cox4a) 
1112.3 3-phosphoglycerate dehydrogenase (Phgdh) 
1120.1 protease (prosome, macropain) 28 subunit, beta (Psme2) 
1123.2 T-complex 1 (Tcp1) 
1127.4 Highly similar to FIBRILLARIN  
1127.4 Weakly similar to T12A2.7.p 
1129.7 Weakly similar to DOC1 MOUSE PUTATIVE ORAL CANCER SUPPRESSOR 
1131.3 discs, large (Drosophila) homolog 2 (chapsyn-110) 
1132.9 Moderately similar to T02345 hypothetical protein KIAA0324 (H.sapiens) 
1134 Highly similar to C143_HUMAN PROTEIN C14ORF3 (PROTEIN HSPC322) 
(H.sapiens) 
1135.8 Highly similar to RUXE_HUMAN SMALL NUCLEAR RIBONUCLEOPROTEIN E 
(M.musculus) 
1140.8 Weakly similar to All-1 protein +GTE form (M.musculus) 
1144.6 small inducible cytokine A5 (RANTES) (Scya5) 
1145.1 Protein disulfide isomerase (Prolyl 4-hydroxylase, beta polypeptide) (P4hb) 
1149.8 GLIA DERIVED NEXIN PRECURSOR (R.norvegicus) 
1154.2 Triosephosphate isomerase 1 (Tpi1) 
1157.7 profilin 
1158.4 Weakly similar to TRANSFORMING PROTEIN RHOB 
1165.3 phosphoglycerate kinase 1  
1168 high mobility group box 2 (Hmgb2) 
1172.5 interferon, alpha-inducible protein 27-like (Ifi27l) 
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1184.4 mama 
1186.2 versican Vint isoform 
1187.3 polymerase (RNA) II (DNA directed)polypeptide G (Polr2g) 
1188.8 Moderately similar to RL22 RAT 60S RIBOSOMAL PROTEIN L22 (R.norvegicus) 
1200.3 Lysyl oxidase  
1204.4 proteasome (prosome, macropain) subunit, beta type, 3 
1214.2 ribosomal protein L5 
1215.7 Highly similar to I56581 dnaK-type molecular chaperone grp75 precursor 
1218.1 amphoterin 
1218.3 Highly similar to IF36_HUMAN EUKARYOTIC TRANSLATION INITIATION 
FACTOR 3 SUBUNIT 6  
1220.1 interferon-inducible protein variant 10 
1228.6 Rps21  
1229.1 Solute carrier family 25, member 5 (adenine nucleotid translocator 2, fibroblast isoform 
1240.8 Highly similar to JC4871 phospholipase C 
1241.5 Highly similar to 40S RIBOSOMAL PROTEIN S25  
1245.1 Highly similar to 40S RIBOSOMAL PROTEIN S28 
1249 thioredoxin (Txn) 
1252 Low molecular mass polypeptide 2 
1256.7 polyubiquitin 
1258.2 Highly similar to EUKARYOTIC INITIATION FACTOR 4A-II (M.musculus) 
1261 Moderately similar to RB48 MOUSE CHROMATIN ASSEMBLY FACTOR 1 P48 
SUBUNIT 
1265.3 Highly similar to BTF3 MOUSE TRANSCRIPTION FACTOR BTF3 (M.musculus) 
1267.2 Il6st 
1270.2 class I beta-tubulin 
1271 Highly similar to 60S RIBOSOMAL PROTEIN L35 
1274.5 ATP citrate lyase (Acly) 
1279.3 NADH ubiquinone oxidoreductase subunit B13 
1287.8 GPI-anchored ceruloplasmin 
1288.8 Weakly similar to cold inducible RNA-binding protein (Rattus norvegicus) 
1296.6 cytochrome oxidase subunit VIc (Cox6c) 
1297.4 nucleoside diphosphate kinase (Nme2) 
1307.3 cellular nucleic acid binding protein 
1307.9 Weakly similar to ROK_HUMAN HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN K 
1312 muscle Y-box protein YB2  
1312.5 Moderately similar to TBB1 RAT TUBULIN BETA CHAIN  
1317.6 peroxiredoxin 1 (Prdx1) 
1322.3 heterogeneous nuclear ribonucleoproteins methyltransferase-like 2 (S. cerevisiae) 
1322.5 granulin 
1324.9 Ferritin subunit H (Fth1) 
1325.4 Best5 protein 
1328.7 Weakly similar to CAG7 RAT ALPHA-N-ACETYLGALACTOSAMINIDE ALPHA-
2,6-SIALYLTRANSFERASE  
1334.9 ribosomal protein L22 
1336.3 ribosomal protein L6 (Rpl6) 
1342.3 protein L29 (Rpl29) 
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1344.5 ribosomal protein S10 (Rps10) 
1350.6 proteasome (prosome, macropain) subunit, alpha type 6 (Psma6) 
1355.4 beta-carotene 15, 15-dioxygenase 
1356.3 Lysyl oxidase (Lox) 
1358.7 cathepsin B (Ctsb) 
1361.7 Highly similar to RADIATION-INDUCIBLE IMMEDIATE-EARLY GENE IEX-1 
(M.musculus) 
1362.3 ribosomal protein L18 (Rpl18) 
1364.6 Highly similar to RUXF_HUMAN SMALL NUCLEAR RIBONUCLEOPROTEIN F 
1371.1 Stromal cell-derived factor 1 
1379 mRNA for ribosomal protein S9  
1396.4 Weakly similar to ARL4 MOUSE ADP-RIBOSYLATION FACTOR-LIKE PROTEIN 4 
(R.norvegicus) 
1399.5 Highly similar to RL11_HUMAN 60S RIBOSOMAL PROTEIN L11 
1403.3 Rat MHC class I RT1 (RT44)  
1403.4 ER-60 protease (ER60) 
1404.3 complement component 1, q subcomponent binding protein (C1qbp) 
1408 CDK110 
1425.8 peroxiredoxin 6 (Prdx6) 
1426.3 secretory leukocyte protease inhibitor (Slpi) 
1432.4 ribosomal protein S15 (Rps15) 
1436.2 H3 histone, family 3B 
1464.1 polyubiquitin 
1466.5 translation elongation factor 1-delta subunit 
1490.3 Aldolase A, fructose-bisphosphate (Aldoa) 
1501 ribosomal protein L14 
1502.8 Highly similar to 2008109A set gene 
1506.4 Rat laminin receptor mRNA, 3 end 
1519.5 schlafen 4 
1526.9 double-stranded RNA-binding protein p74 
1530.7 ribosomal protein S11 
1541.1 calpactin I heavy chain 
1541.7 guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 (Gnb2l1) 
1555.3 stearyl-CoA desaturase 
1571.8 R5RT18 ribosomal protein L18a, cytosolic (validated)  
1581.4 thymosin, beta 10 (Tmsb10) 
1598.4 ribosomal protein L24  
1604 Highly similar to OAZ RAT ORNITHINE DECARBOXYLASE ANTIZYME 
1609.4 Solute carrier family 11 member 2 (natural resistance-associated macrophage protein 2) 
(Slc11a2) 
1611.5 CDK105 protein (Cdk105) 
1613.7 Enolase 1, alpha (Eno1) 
1619.9 Weakly similar to JC6554 probable serine proteinase 
1620.4 Highly similar to B46746 glycine hydroxymethyltransferase  
1620.9 Highly similar to 60S ACIDIC RIBOSOMAL PROTEIN P2 
1627.1 ribosomal protein S27a 
1632.2 Moderately similar to RL34 RAT 60S RIBOSOMAL PROTEIN L34 
1633.3 Highly similar to ERH_HUMAN ENHANCER OF RUDIMENTARY HOMOLOG 
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1662.8 Highly similar to RS3 MOUSE 40S RIBOSOMAL PROTEIN S3 
1667.6 PHOSPHOGLYCERATE KINASE, TESTIS SPECIFIC 
1672.8 ribosomal protein L15 
1676.4 Moderately similar to HS9B RAT HEAT SHOCK PROTEIN HSP 90-BETA  
1679.5 RAN, member RAS oncogene family (Ran) 
1685.3 Highly similar to RL8_HUMAN 60S RIBOSOMAL PROTEIN L 
1693.4 ribosomal protein L21 (Rpl21) 
1702.8 proliferation related acidic leucine rich protein PAL31 (PAL31) 
1704.7 type AB hnRNP protein p40 
1714 chondroitin sulfate proteoglycan 2  
1716.9 Moderately similar to Y101_HUMAN HYPOTHETICAL PROTEIN KIAA0101  
1719.4 interferon inducible protein 10 (IP-10) 
1720.1 Ribosomal protein S5 
1722 Nucleoplasmin-related protein (Nuclear protein B23 (Npm1) 
1723.7 golgi SNAP receptor complex member 1 
1738.7 ribosomal protein L10a (Rpl10a) 
1739.2 hypothetical RNA binding protein RDA288 
1740.1 UDP-glucose dehydrogeanse (Ugdh) 
1743.4 tumor protein, translationally-controlled 1 (Tpt1) 
1745.2 ribosomal protein S2 
1753.2 nuclease sensitive element binding protein 1 
1767.5 B-cell translocation gene 1, anti-proliferative (Btg1) 
1776.4 Weakly similar to AF154572 1 ERG2 protein 
1788 ribosomal protein L28 (Rpl28) 
1791.6 Highly similar to SUI1 MOUSE PROTEIN TRANSLATION FACTOR SUI1 
HOMOLOG 
1792.5 Rps24 
1807.7 HS9B RAT HEAT SHOCK PROTEIN HSP 90-BETA 
1816.7 ribosomal protein S27 (Rps27) 
1826.7 ribosomal protein S14 (Rps14) 
1832 ribosomal protein S26 (Rps26) 
1832.2 Beta-2-microglobulin (B2m) 
1835.7 Glyceraldehyde-3-phosphate dehydrogenase (Gapd) 
1841 protein L4 (Rpl4) 
1856.8 H2A histone family, member Z (H2afz) 
1857.8 Highly similar to 60S RIBOSOMAL PROTEIN L23A  
1875.7 Tuba1  
1884.5 Highly similar to 60S ACIDIC RIBOSOMAL PROTEIN P1 
1885.3 poly(A) binding protein, cytoplasmic 1 (Pabpc1) 
1890.5 Hexokinase 3 (Hk3) 
1891.2 ribosomal protein S3a (Rps3a) 
1899.6 Liver activating protein (LAP, also NF-IL6, nuclear factor-IL6, previously designated 
TCF5) (Cebpb) 
1906.8 ribosomal protein S7 
1915.9 heat shock 70kD protein 8 (Hspa8) 
1919 ribosomal protein S23 
1931.9 ribosomal protein L35a 
1967.8 ribosomal protein L13 
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1971.7 Nucleolin (Ncl) 
1977.4 ribosomal protein L37 
1997.3 Highly similar to RL7A_HUMAN 60S RIBOSOMAL PROTEIN L7A 
1997.5 Highly similar to EF1B_MOUSE Elongation factor 1-beta (EF-1-beta) 
1998.7 Ryudocansyndecan 4 (Sdc4) 
2006.4 ribosomal protein S17  
2007.4 Highly similar to 40S RIBOSOMAL PROTEIN S20 
2009.5 ribosomal protein L30 (Rpl30) 
2013.4 laminin receptor 1 (Lamr1) 
2014 CINC-2 alpha 
2021.6 Highly similar to T30827 nascent polypeptide-associated complex alpha chain, non-
muscle splice form - mouse  
2054.2 Highly similar to RL9 RAT 60S RIBOSOMAL PROTEIN L9 
2064.3 Highly similar to 40S RIBOSOMAL PROTEIN S16  
2066 Highly similar to RS18_HUMAN 40S RIBOSOMAL PROTEIN S18  
2068.5 ribosomal protein S6 (Rps6) 
2082.9 activating transcription factor ATF-4 (Atf4) 
2102.1 heat shock protein 60 (liver)  
2109.6 ribosomal protein S8 (Rps8) 
2114.2 unknown Glu-Pro dipeptide repeat protein 
2120.4 Heat shock 10 kD protein 1 (chaperonin 10) (Hspe1) 
2129.5 Highly similar to ubiquitin-like protein ribosomal protein S30 
2145.4 Weakly similar to HG17 RAT NONHISTONE CHROMOSOMAL PROTEIN HMG-17 
2167.6 Superoxide dismutase 2, mitochondrial 
2193.6 Highly similar to RL12 RAT 60S RIBOSOMAL PROTEIN L12 
2207.8 Highly similar to HS9B RAT HEAT SHOCK PROTEIN HSP 90-BETA 
2210.3 ribosomal protein S2 
2217.3 Highly similar to SUI1 MOUSE PROTEIN TRANSLATION FACTOR SUI1 
HOMOLOG 
2219.5 tropomyosin 3 
2225.3 Moderately similar to MCA3_HUMAN Multisynthetase complex auxiliary component 
p18 
2228.2 Highly similar to S22655 translation elongation factor eEF-1 gamma chain 
2232.2 small inducible cytokine subfamily D, 1 (Scyd1) 
2245.2 R.norvegicus ASI mRNA for mammalian equivalent of bacterial large ribosomal subunit 
protein L22 
2277.9 lipid-binding protein  
2287.1 acidic ribosomal protein P0 (Arbp) 
2331.3 ral simian leukemia viral oncogene homolog A  
2364.2 ribosomal protein L19 
2371.7 ribosomal protein S13 
2395.2 Highly similar to 60S RIBOSOMAL PROTEIN L37A 
2447.3 ribosomal protein S12 
2496.8 ribosomal protein L41 
2521.4 ribosomal protein L29 
2528.7 IKBA_RAT NF-kappaB inhibitor alpha  
2586.1 Ribosomal protein S29  
2588.7 serine protease  
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2713.8 Highly similar to RL26 RAT 60S RIBOSOMAL PROTEIN L26 
2720.3 Moderately similar to A25113 tubulin beta chain 15 
2742.8 Highly similar to RL3 RAT 60S RIBOSOMAL PROTEIN L3 
2766.7 plasminogen activator inhibitor 2 type A (Pai2a) 
2840 Weakly similar to HE47 RAT PROBABLE ATP-DEPENDENT RNA HELICASE P47 
2946.4 Highly similar to 40S RIBOSOMAL PROTEIN S19 
3005.8 ribosomal protein S15a 
3139.5 adhesion molecule 1 (Icam1) 
3220.7 ribosomal protein L31 (Rpl31) 
3307.1 CINC-2 alpha 
3407.5 CC chemokine ST38 precursor 
3466 CINC-2 alpha 
3950.6 lipocalin 2 (Lcn2) 
4519.9 metallothionein-2 and metallothionein-1 genes 
4725.1 RAT SMALL INDUCIBLE CYTOKINE A7 PRECURSOR 
5023.5 Weakly similar to nerve growth factor 
7587.8 Superoxide dismutase 2, mitochondrial  
7699.1 SERUM AMYLOID A-3  
8461.8 Small inducible gene JE (Scya2) 
9409.1 gro 
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 Figures 3, 4, 6 
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